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Initium est dimidium facti.
(Once you started you are halfway there.)
Latin Proverb
1 Introduction 
1.1 Plants and plant viruses as expression system for peptide-
vaccines  
As an alternative to bacteria, yeast, insect and mammalian cell culture as well as 
transgenic animals, plants have emerged as expression system for the production of 
heterologous proteins within the last fifteen years. The advantages of plants as 
production systems include economical large-scale production, the absence of 
contaminating mammalian pathogens and therefore safety, and the ability to produce 
complex, biologically-active proteins since plants have similar pathways of protein 
synthesis, secretion, folding and post-translational modifications to animal cells, with 
only minor differences in protein glycosylation. As a result, a large number of 
different proteins have been expressed in planta, including enzymes, plasma proteins 
hormones, cytokines, interleukins, recombinant antibodies and vaccines. (reviewed in 
[1-4]). 
In order to produce heterologous proteins in plants the foreign cDNA has to be 
introduced into the plant cell. For this plants can either be stably transformed so that 
the foreign gene is permanently inserted into the plant genome or are used for 
transient expression. The latter has several advantages including time-efficiency, 
higher levels of protein expression, flexibility and convenience in the modification of 
existing products, the selection of a suitable production host and ease of scale-up. 
Transient protein expression can be achieved via Agrobacterium infiltration [5] or by 
plant virus expression vectors [6]. For virus-based protein expression the foreign 
cDNA is inserted into the viral genome so that, upon infection of the host plant cell, 
the transgene is replicated and expressed along with native viral genes. Furthermore, 
target proteins, particularly antigenic peptides, can be genetically fused to viral coat 
proteins. In this case the plant virus is not only used for expression but also for 
antigen presentation and delivery. 
Plant viruses are of special interest for the production, presentation and delivery of 
immunogenic peptides and consequently for use as vaccines [7, 8]. Unlike most 
animal viruses, plant viruses are not infectious in humans and animals; their structure 
is very simple, and often formed with a single coat protein (CP). Additionally, most 
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plant viruses are not enveloped and many accumulate to very high levels in their 
hosts. Like liposomes and microcapsules plant viruses are expected to endure the 
passage through the gastrointestinal tract, if they are contained within the plant cell, 
allowing oral administration and the generation of peripheral and mucosal immunity 
[9]. Finally, the ease of virus production, purification and scale-up, enhanced peptide 
immunogenicity and stability, makes this system a very promising tool in vaccine 
development. Consequently a wide number of plant viruses are currently being 
investigated including Alfalfa Mosaic Virus (AlMV) [9, 10], Cowpea mosaic virus 
(CPMV) [11, 12], Tobacco mosaic virus (TMV) [7, 13],  Plum pox virus (PPV) [14], 
Odontoglossum ringspot virus (ORSV) [15],  Tomato bushy stunt virus (TBSV) [16], 
Cucumber mosaic virus (CMV) [17], Johnsongrass mosaic potyvirus (JGMV) [18], 
Potato virus X (PVX) [19, 20] and Zucchini yellow mosaic virus (ZYMV) [21]. Table 
1-1 gives a summary of plant viruses used for the presentation of immunogenic 
peptides or other functionally active molecules. Reviews are found within [6, 22, 23]. 
Table 1-1: Plant viral CPs used for the presentation of immunogenic peptides or other functionally 
active molecules 
Viral CP Pathogen/Protein Function / purpose Reference 
AlMV RSV, HIV, RV B-cell epitopes [9, 24, 25] 
FMDV, HRV, HIV, CPV, Ps.aeruginosa  B-cell epitopes [12, 13, 26] 
GFP  Analysis [27] 
Protein A Kinase derived peptide Anchoring point  [28] 
CD46  Antiviral, entry inhibitor [29] 
CPMV 
Cysteine mutants Chemical reactivity [30] 
CMV HCV B-cell epitopes [17] 
P. falciparum B-cell epitopes 
Luteinizing hormone releasing hormone Decapeptide hormone JGMVE.coli
S. japonicum Full-length protein antigen 
[18] 
ORSV Nocistatin Neuropeptide [15] 
PPV CPV B-cell epitopes [14] 
GFP Analysis [31] 
Anti diuron scFv single chain antibody fragment [32] 
HIV B-cell epitopes [19] PVX 
BNYVV Multiple B-cell epitopes [20] 
Ps.aeruginosa, MHV, RV, FMDV, 
murine zona pellucida ZP3 protein B-cell epitopes 
[13, 33-35] 
[7] 
Nocistatin Neuropeptide [15] TMV 
TMOF peptide  insecticide  [36] 
 
CPV: Canine Parvovirus; BNYVV: Beet Necrotic Yellow Vein Virus; FMDV: Foot and Mouth 
Disease Virus; GFP: Green fluorescent protein; HCV: Hepatitis C Virus; HIV: Human 
Immunodeficiency Virus; HRV: Human Rhino Virus; JGMVE.coli: Johnson Grass Mosaic Virus 
particles recombinantly produced in E. coli;  MHV: Murine Hepatitis Virus; Ps. aeruginosa: 
Pseudomonas aeruginosa; P. Falciparum: Plasmodium Falciparum;  RSV: Respiratory Syncytial 
Virus; RV: Rabies Virus; scFv: single chain Fv antibody fragment; S. japonicum: Schistosoma 
japonicum;  TMOF: trypsin modulating oostatic factor. 
 
1 Introduction                                                                                                                                           11 
Several immunological studies have been carried out elucidating effectiveness of 
plant viruses as peptide delivery tools that have potential as vaccine candidates. For 
example, Koo et al. (1999) used chimeric TMV particles displaying the 5B19 epitope 
from the spike protein of murine hepatitis virus (MHV) to immunize mice 
intranasally. The mice not only developed high IgG and IgA titers but survived 
challenge with a lethal dose of MHV [33]. In another studies, Nicholas et al. (2002) 
compared the immune response in mice upon subcutaneous and intranasal 
immunization with a 17-mer from the canine parvovirus presented on CPMV or 
conjugated to keyhole limpet haemocyanin (KLH). Anti-peptide IgA was detected in 
intestinal and bronchial lavage fluid, demonstrating that a mucosal immune response 
to chimeric plant viruses can be generated by systemic and mucosal immunization 
with chimeric plant virus vaccines. Furthermore, neutralizing serum antibodies were 
generated. Interestingly, the CPMV-presented peptide showed a marked TH1 bias, as 
determined by IgG2a isotypes, whereas the KLH-conjugated peptide generated an 
IgG1-biased TH2 response [26].  
Besides the display of antigenic peptides plant viral particles have also been used as 
scaffolds for peptide drugs [29] and functional display of ligands by bio-conjugation 
[28]. Khor et al. (2002) utilized the CPMV platform to create an antiviral agent 
against measles virus (MV) by displaying a CD46- derived peptide known to inhibit 
MV infection [29]. The CPMV-CD46 chimera efficiently inhibited MV infection, 
while wild-type CPMV did not, and was up to 100-fold more effective than the 
soluble CD46 peptide. Chatterji et al. (2002) inserted a Protein A kinase anchoring 
protein-derived peptide on the surface of CPMV that could serve as anchoring point 
for a wide range of recombinant proteins that contain the corresponding binding 
peptide [28]. Furthermore plant viral particles have been used as supra-molecular 
building blocks with potential applications in biochemistry, materials science, and 
catalysis. For this purpose reactive residues like cysteine or lysine were integrated at 
their surface to allow disulfide bond formation, binding of metallic gold, and selective 
biochemical reactivity at the introduced residues [30, 37].  
1.1.1 Alfalfa Mosaic Virus (AlMV) 
Alfalfa Mosaic Virus (AlMV) is the type species of the genus Alfamovirus and 
belongs to the family Bromoviridae [38]. AlMV was first reported in 1931 as a 
pathogen of alfalfa (Medicago sativa) [39]. A great variety of natural susceptible plant 
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species are known, including the agricultural crops tobacco (Nicotiana tabacum), 
beans (Phaseolus vulgaris), soybean (Glycine max), potato (Solanum tuberosum), 
tomato (Lycopersicon esculentum) and lettuce (Lactuca sativa) [40, 41]. The virus is 
distributed world wide and transmission can occur via insects, grafting, mechanical 
inoculation, and by seeds or by pollen to seed [40]. A wide range of symptoms have 
been reported ranging from symptom less to mosaic, mottle, malformations, necrotic 
or chlorotic local lesions, systemic stem necrosis or plant death [40]. Symptoms either 
persist or disappear soon after infection, depending on the host and environmental 
conditions [41]. 
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Figure 1-1: Genome organization of AlMV adapted from Bol (1999) [38] 
Shown are the three genomic RNAs (RNA1, 2, 3) and the sub-genomic RNA 4 and their gene products 
P1, 2, 3 and CP. P1 contains a methyltransferase and helicase activity; P2 has polymerase activity 
with the conserved GDD motif. Together they form the replication complex. They also have been stably 
transformed into tobacco after removing of 36 5’ nt in RNA1 and 10 nt 3’ nt in RNA2 to generate P12 
plants. P1, P2 and P3 are produced from genomic RNA. CP is produced from subgenomic RNA4. 
RNA3 was cloned into pSP65 to generate pBR.. P3 is involved in cell-to-cell movement, and CP is 
required for genome activation, RNA replication, virus assembly, RNA stability, long distance 
movement and symptom formation. 
AlMV has a tripartite RNA genome of plus strand polarity (Figure 1-1). Genomic 
RNA1 encodes P1 protein with putative methyltransferase and helicase activity. 
Genomic RNA2 encodes P2 protein containing a GDD motif of viral plus-strand RNA 
polymerases. P1 and P2 have been identified as subunits of the purified AlMV RNA-
dependent RNA polymerase complex (RdRp) [42]. The P3 protein encoded by RNA3 
is involved in viral cell-to-cell movement. Subgenomic RNA4 that is produced from 
RNA3 serves as messenger RNA for the multifunctional coat protein (CP) [43]. 
The four viral RNAs are separately encapsidated into non-enveloped bacilliform or 
spherical particles (Figure 1-2). These particles have a constant diameter (18nm) but 
variable lengths (30, 35, 43, and 56 nm) depending on the size of the encapsulated 
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RNA [44]. RNAs 1, 2 and 3 are encapsidated in virus particles that contain 240, 186 
and 150 CP subunits, respectively. RNA4 is encapsidated by 132 CP subunits into 
bacilliform or spherical particles. In the absence of RNA, CP assembles into T=1 
icosahedral particles, with a diameter of 21nm and prominent holes (3.8nm) [45, 46], 
that can be crystallized [47]. 
 
 
 
Figure 1-2: Electromicrograph of AlMV particles  
Negative contrast electron micrograph of AlMV particles 
taken from the ICTVdB page [48]. The different size of 
the bacilliform particles correspond with the size of the 
encapsidated genomic RNA 1, 2 and 3. Encapsidated 
subgenomic RNA 4 results in spherical or bacilliform 
particles. 
 
In order to be fully infectious the three genomic RNAs and few CP molecules are 
needed [38]. Transgenic tobacco plants expressing RNA1 and 2 were created to 
simplify the inoculation process [49] (Figure 1-1). In these P12 plants, the integrated 
cDNAs lack the 5’-terminal 36 nucleotides (nt) of RNA 1 and the 3’-terminal 10nts of 
RNA2. The truncated RNAs 1 and 2 are not replicated by the transgenic RdRp and 
consequently no wild type-like virus can be produced [43, 49], when infected with 
RNA3. This makes P12 plants a safe and convenient production system. Also, the P12 
plants can be infected with RNA3 without the requirement of CP. Recently RNA3 has 
also been engineered into an expression vector (Figure 1-1, Figure 3-2), allowing the 
expression and presentation of peptides as coat protein fusions in P12 plants [50]. 
 
AlMV CP consists of 220 amino acid residues and has a size of ~24kDa. It is 
involved, as already seen above, in multiple steps of the viral replication cycle [38] 
including genome activation [51, 52], RNA replication [53, 54], virus assembly [55, 
56], stability of viral RNA [57], long distance movement of viral RNA [58] and 
symptom formation [59]. In order to fulfill these tasks it needs to interact with 1) viral 
RNA and self assemble, 2) the replication complex, 3) movement protein and, 4) plant 
defense proteins.  
AlMV CP has a canonical eight-stranded β-barrel fold, which is common for most 
spherical viruses [38]. It forms very stable dimers in solution [45]. For CP-CP dimer 
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formation the C-terminal arm of one CP hooks around the N-terminal arm of the 
twofold related subunit and becomes sandwiched between this N-terminal arm and the 
body of the β-barrel of the partner [46, 60]. The dimer is further stabilized through 
interactions of the C-terminal arms at the icosahedral twofold axis [46]. Interestingly 
the N-terminal end seems not to be involved in viral assembly and is presented at the 
surface of the virus particles. 
CP-RNA interaction occurs between the N terminus of CP and the 3’ end of the three 
AlMV RNAs, which fold into five stem-loop structures, flanked by single stranded 
AUGC boxes [38]. Deletion of specific CP regions or even single amino acids [52], 
have identified specific amino acids in CP that function in genome activation, RNA 
replication, stability and movement.  
Finally, CP is known to be involved in symptom formation [59]. Generally, symptoms 
are induced through direct or indirect interaction between the plant virus and its host. 
If the virus is able to systemically infect the plant and consequently change its 
metabolism, symptoms like mosaic, mottle, malformation or reduced growth might 
result [61]. On the other hand, symptoms like necrosis are the result of a plant defense 
reaction mounted to contain the virus at its site of infection [62]. The latter is known 
as the hypersensitive response (HR) and it was shown that a molecular recognition 
event triggers this reaction [61-63]. The interaction occurs thereby between pathogen 
avirulence (avr) gene loci and alleles of the corresponding plant disease resistance (R) 
locus. When corresponding R and avr genes are present in both host and pathogen, the 
result is disease resistance and HR-symptom formation, if either is inactive or absent, 
disease results [62, 64-68]. 
As seen above AlMV CP is involved in major steps of the viral life cycle. Inspite of 
this, AlMV CP has proven to be useful as an epitope presentation system [24, 25, 41]. 
Until now, peptides up to a length of 38 aas have been inserted at the N-terminus of 
CP and the resulting chimeric CPs formed particles that presented the foreign peptide 
on their surface, which retained biological activity [25, 69]. Until now, epitopes from 
the rabies virus, HIV1 and RSV were successfully produced as AlMV-CP fusions. 
Chimeric rabies-AlMV infected spinach leaves when fed to mice [9] and in human 
trials [25] induced protective serum IgGs and IgAs as well as mucosal IgAs. The trials 
suggested that plant virus particle-based vaccines might be used in prime-boost 
regimens.  
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1.2 Respiratory Syncytial Virus 
1.2.1 The Virus  
Human respiratory syncytial virus (RSV) is an enveloped, non-segmented negative-
stranded RNA virus classified in the Paramyxoviridae family, genus Pneumovirus, 
order Mononegavirales [70].  
Its genome comprises a single strand of negative-sense RNA 15,222 bp in length (A2 
strain) that is tightly associated with viral protein from the nucleocapsid. A viral 
polymerase is packed within the virion and transcribes genomic RNA into mRNA. 
Eleven genes are known. They are encoding trans-membrane surface proteins (G, F, 
and SH), two matrix proteins (M1 and M2), three nucleocapsid proteins (N, P and L), 
two nonstructural proteins (NS1 and NS2) and two transcription regulation factors 
(M2-1, M2-2) [70, 71]. The 3 trans-membrane proteins, the fusion protein (F), the 
attachment protein (G) and the small hydrophobic protein (SH) are contained in a 
plasma membrane derived lipid bilayer and form the viral envelope (Figure 1-3). 
 
 
 
Figure 1-3: A) Electron micrograph of RSV and B) schematic diagram of RSV. Taken from 
Brandenburg et al. (2001) [72] 
 
The F protein together with the G and SH protein mediates fusion of the viral 
envelope with the hosts cell membrane prior to viral entry. The F protein also 
mediates viral spread from cell to cell, resulting in the characteristic syncytial 
formation [70, 71, 73]. Both F and G are glyco-proteins, and the only viral 
components known to induce neutralizing antibodies (n-abs). They are important 
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targets for subunit vaccine development [71, 74, 75]. Recently also cytotoxic T-cell 
(CTL) epitopes were found within the F [76, 77] but not the G protein. Antigenic and 
sequence diversity between the different RSV strains as well as between different 
paramyxoviruses is high in the G [78], but low for the F protein [79]. This led to a 
further classification of RSV into two sub-groups A and B, which differ by 53% in the 
G but only 11% in the F sequence. The RSV F protein is therefore a potential target 
for the development of subunit and peptide vaccines because it stimulates the 
production of n-abs and cytotoxic T cell responses, but also can protect against two 
different sub-groups. 
1.2.2 The Fusion Protein 
The F protein is synthesized as a single N-glycosylated polypeptide of 574 aas [73]. 
Its signal peptide (aa 1-21) directs the polypeptide into the rough endoplasmatic 
reticulum (rER), where the polypeptide is assembled into a homo-oligomer (F0) and 
the signal peptide is removed. The F0-precursor is cleaved by a cellular furin protease 
at furin cleavage sites I (aa 106-109) and II (aa 132-136), releasing a cleavage peptide 
of 27aa (aa 110-136) [80, 81]. The two chains generated by cleavage, F1 (aa 137-574) 
and F2 (aa 22-109), are connected through a disulfide bridge between C69 and C212. 
Via its trans-membrane domain (aa 525-550) the mature F-protein is anchored within 
the hosts cell membrane [82]. The intracellular domain (aa 551-574) is not known to 
have any particular function. The extra-cellular part of the F-protein contains the 
Fusion peptide (aa 137-148) and three heptad repeat domains (HR1; aa 149-206, 
HR2; aa 474-523, HR3; aa 53-100) [79](Figure 1-4, Figure 3-1).  
In order to mediate viral fusion the F-protein has to undergo conformational changes 
[83, 84] in which the fusion peptide HR1 and HR2 are involved [73]. In the native, 
non-fusogenic state, the fusion peptide and HR1 are not accessible. Upon activation, 
in the intermediate state, HR1 is exposed allowing the fusion peptide to project into 
the host’s cellular membrane. Finally, in the fusogenic state HR2 associates with HR1 
and forms a hairpin-like structure which facilitates apposition of the viral and cellular 
membranes [85]. The intermediate state is vulnerable to inhibition. HR2-derived 
peptides as well as other small molecule inhibitors bind to the exposed HR1 
preventing HR1-HR2 association [85-87]. T-118, a peptide comprising the RSV F 
HR2 residues 488 to 522, was shown to potently inhibit viral fusion [79]. This peptide 
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inhibition has been described also for the human immunodeficiency virus (HIV), 
human parainfluenza virus (HPIV) and measles virus (MV) [79].  
 
Figure 1-4: Prediction of secondary-structure of the F protein adapted form Lopez et al. (1998) [88].  
(A) Linear diagram of the F protein polypeptide, showing cysteine residues (•), potential N-
glycosylation sites (little trees), site of proteolytic processing (↓), amino acid changes in escape 
mutants (black triangles) and hydrophobic regions (black rectangles). S-S, disulfide bridge. 
(B) Predicted secondary-structure elements of the F protein: a-helices (cylinders), b-sheets 
(rectangles), loops (turns). Other symbols are as explained for panel A. The segment between 
residues 255 and 275 (F255-275), predicted to fold in a helix-loop-helix structure, is boxed. F1h 
and F2h, amphipathic a-helices in the F1 and F2 chains, respectively. The diagram is not drawn to 
scale. The predictions were made with published sequences of pneumovirus F proteins and by 
using secondary structure prediction algorithms available on Worldwide Web servers (for details 
see [88]). The final secondary-structure model was a consensus of the information obtained by the 
different methods. 
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In fact a peptide inhibitor (T-20) homologue to a portion of the HR2 of HIV-I, has 
been shown in clinical trials to significantly reduce plasma viral loads in a broad 
range of HIV-infected patients [89]. Besides peptide inhibitors other small molecules 
are currently tested as viral entry inhibitors [86, 87, 90, 91]. 
Several RSV-F B-cell epitopes and antigenic areas are described in literature (Table 
3-5). All of them are within the F1 part of the F protein in an area ranging from aa 173 
to aa 488, but mainly between aa 173 to aa 298 [74, 88, 92-98] and aa 390 to aa 488 
[88, 99].  
Compared with the identification of B-cell epitopes fewer reports have described the 
identification of CD8 or CD4 T-cell epitopes. Brandenburg et al. (2000) identified 
epitopes between residues 118 to 126 and 551 to 559 using peripheral blood 
mononuclear cells (PBMC) from two infants that had recently recovered from a 
severe, laboratory-confirmed RSV infection [76]. CD4 epitopes have been identified 
within residues 328 to 355 [100] and throughout the whole F-protein [101]. 
1.2.3 Disease, treatment and vaccines 
RSV infects the respiratory tract. Clinical manifestations range from mild upper tract 
illness to bronchiolitis and pneumonia. In infants and children RSV is the most 
important cause of lower respiratory tract illness [71, 102, 103]. By the age of two 
almost all children have been infected with RSV, half of them twice [104]. This leads 
to hospitalization of approximately 100,000 children in the USA per year. Mortality 
among hospitalized children is estimated to be 1-3% [103]. Besides being a pediatric 
pathogen RSV also causes disease in the elderly [105], immune suppressed 
individuals [106] and adults [107, 108].  
Ribavirin, the only antiviral agent approved for the treatment of RSV infection has 
limited utility due to efficacy and toxicity issues [109]. Two prophylactic therapies 
applying a polyclonal RSV immunoglobulin (RSV-IVIG) [110] or a human 
monoclonal antibody targeting the RSV Fusion protein (Synagis/palivizumab) [111, 
112] are solely administered to high-risk infants. Another potential therapeutic is 
HNK20 a mouse monoclonal IgA that binds to the F protein and neutralizes the virus 
in vitro and in vivo. HNK20 has been humanized [113] and was successfully 
investigated in preclinical trials [114, 115]. However, its binding site and mode of 
action is yet unknown.   
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Table 1-2: Comparison of different vaccination approaches against RSV 
Vaccine candidate Major advantages Major disadvantages References 
Formalin inactivated RSV  Disease exacerbation (DE) [116-118] 
Purified proteins 
(PFP 1&2) 
Controlled manufacturing 
Safe in adults and the elderly 
DE not ruled out              
No CTL response [119-122] 
Peptide (BBG2Na) Controlled manufacturing Safe in adults and the elderly 
DE not ruled out               
No CTL response [123-127] 
N
on
-r
ep
lic
at
in
g 
Su
bu
ni
ts
 
ISCOMS 
Virosomes 
Induction of n-abs and 
CTLs, even in presence of 
maternal abs 
Only preclinical data [128-130] 
Live attenuated Mimics natural infection   No DE 
Over/under attenuation 
Reversion to wild typ 
[71, 131-
133] 
DNA-vaccine Controlled manufacturing Induction of n-abs and CTL 
Only preclinical data       
DE not ruled out [134-137] 
R
ep
lic
at
in
g 
Vector delivery systems Induction of n-abs and CTL Limited immunogenicity Only preclinical data [138, 139] 
 
Major advantages and disadvantages of currently pursued RSV vaccination approaches. DE: disease 
exacerbation; CTL: cytotoxic T-Lymphocytes; n-abs: neutralizing antibodies; abs: antibodies. PFP: 
purified F protein; BBG2Na: residues 130 to 230 of RSV-A G protein (G2Na) fused to BB, an 
albumin-binding domain of streptococcal protein G; ISCOMS: immune stimulating complexes; 
Virosomes: RSV-F protein associated with influenza virosomes (RSV-F/IRIV). Table adapted from 
Brandenburg et al. (2001) [72]. 
 
Forty years of research have not led to a safe and effective vaccine due to a 
combination of complicating factors: (i) RSV infection in infants occurs at a very 
young age when the immune system is immature and maternal antibodies are present. 
Both factors reduce effectivity of immunization, which should be carried out almost 
immediately after birth [72]; (ii) frequent re-infections throughout life-time, making 
the induction of sterile immunity rather unrealistic [140] (iii) disease exacerbation 
observed after immunization with a formalin-inactivated whole virus vaccine [141].    
The latter was evaluated in the mid 1960s in infants and children, but failed to induce 
a protective immune response. Subsequent natural infection increased the frequency 
and severity of RSV-associated disease significantly [70]. Several factors contributed 
to this disease exacerbation. First, due to the parenteral administration of the vaccine 
no local respiratory tract RSV-specific secretory IgA antibodies were generated which 
could have prevented viral entry and infection. Second, no n-abs were generated even 
if high antibody titers were reached [70]. Third, the vaccine failed to increase the 
levels of RSV-specific CTLs but augmented those of T-helper cells [142]. Fourth, the 
T-helper cell response was biased towards a TH2 type [143].  
Disease exacerbation upon RSV re-infection could be prevented in BALB/c mice by 
depletion of CD4+ cells [116] and TH2 type cytokines IL-4 and IL-10 [117]. It 
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remains unclear if the increase in total CD4+ cells or the TH2 type is most important 
in the immunopathologic response [70].  
Since the formalin-inactivated vaccine failed virtually all-modern vaccine 
development approaches are currently pursued, including live-attenuated RSV, 
recombinant and virus produced subunit vaccines, DNA vaccines and peptide 
vaccines. Their advantages and drawbacks are summarized in Table 1-2; a detailed 
comparison gives the review from Brandenburg et al. (2001) [72]. 
1.3 The immune response to viruses 
Human life is constantly threatened by invading viruses as well as other pathogens. 
Fortunately, most pathogens are successfully recognized, contained, eliminated and 
resulting disease prevented. Pathogen defense occurs thereby at different levels. 
Transmission of pathogen is blocked if it cannot overcome the host’s physicochemical 
defense barrier or is eliminated through the innate immune system. Viral infection is 
prevented if the pathogen is neutralized through abs secreted by B-cells before it is 
able to infect its host cells. Finally, disease is modified or prevented if infected cells 
are cleared through effectors of cellular immunity, which rely on T-lymphocytes. 
[144]. All these activities contribute to viral immunity, but only T- and B-cell based 
responses are antigen-specific and able to establish “memory”. These mediators of 
acquired antigen-specific immunity are the prime targets for vaccine development. 
Their function is controlled by Dendritic Cells (DCs), which initiate and modulate the 
immune response [145, 146] (Figure 1-5).  
1.3.1 Antibody mediated immunity against viruses 
The over-all contribution of abs to viral immunity is still hotly debated [145]. 
Opinions range from the view that antibodies are required primarily to clear bacterial 
rather than viral infection [144] to the view that they are the only protecting agent 
successfully induced by vaccination [147]. Antiviral activities of antibodies can be 
grouped into those against free virus particles and those against infected cells [145]. 
The first can protect cells from viral infection through neutralization, complement-
mediated lysis and phagocytosis. The latter mediate lysis of infected cells, inhibition 
of viral replication, virus release and cell-to-cell transmission. 
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Figure 1-5: Schematic overview of the immune response to viruses; adapted from [148] 
Shown are the three main arms of the human immune response to viruses and their interactions. The 
humoral response is represented by B- and Plasma Cells; the cellular response is represented by 
Cytotoxic T Lymphocytes (CTL) and T-helper cells (TH); antigen presenting cells (APCs) are 
represented by Dendritic cells (DCs). Further details are given in the text (1.3.1, 1.3.2 and 1.3.3). 
Abbreviations used are explained in section (7.1). 
  
By far the most desirable activity of an antibody is neutralization of free virus in vivo. 
Neutralization is defined as loss of viral infectivity as a result of antibody binding that 
occurs without the involvement of any other agents [145]. The mechanism of 
neutralization is still unclear. N-abs could induce conformational changes within the 
envelope or capsid proteins, which would then prevent viral entry; block viral un-
coating; bind virus so that viral attachment and fusion are inhibited by the sole 
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presence of the abs. Neutralizing activity of an ab is related to its affinity and avidity 
for virion surface antigens; high affinity binders are therefore desirable [145].  
At the same time non-neutralizing antibodies contribute to viral clearance. They do so 
through the Fc-mediated effector system. First the activation of complement and 
deposition of complement components through viral bound antibodies can enhance 
neutralization. Second complement activation can lead directly to virolysis. Third Fc 
and complement receptors can bind antibody- and complement-coated virions, which 
leads to phagocytosis and viral inactivation. A very good review of the role of abs in 
antiviral vaccines is given by Burton (2002) [145].  
 
Generation of n-abs is the most desirable B-cell response as a consequence of 
vaccination. However, out of the many antibodies generated, when immunizing with 
whole attenuated or killed virus and even viral subunits, only few confer 
neutralization and protection. Besides generating non-neutralizing abs those 
determinants might be toxic or able to generate an immunopathologic response. It is 
therefore most favorable to exclude all unwanted immunogenic determinants and only 
raise B-cell responses against neutralizing epitopes. Peptide vaccines or small subunit 
fragments are able to generate such a specific response. Unfortunately many B-cell 
epitopes are conformational and cannot be presented by linear peptides or mis-folded 
protein fragments [149].  
Structural epitopes can be identified and even generated exploiting already existing n-
abs. This concept is know as “reverse vaccinology” [145], since antigen is generated 
from antibody and not antibody from antigen. A neutralizing antibody could be used 
to screen synthetic peptides [150-152], recombinant peptides [153], antigen fragment 
[154] or DNA-shuffled libraries [155]. Peptides of high affinity are selected and their 
sequence analyzed. If it is homologous to the primary amino acid sequence of the 
antigen a linear epitope is identified and its position within the antigen is now known. 
This approach is therefore also used for epitope mapping [154]. If no homology is 
found, the peptide is likely to mimic a structural, discontinuous epitope, especially if 
it is able to compete with the native antigen for antibody binding. Such a peptide is 
referred to as mimic. If a mimic is further able to induce antibodies with the same 
biological activity, i.e. neutralization, as the antibody used as template, it is called a 
mimotope [149].  
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1.3.2 T-cell mediated immunity against viruses 
In contrast to B-cells, T-cells are not able to recognize ag directly through their T-cell 
receptor (TCR) [156]. The ag needs to be processed and presented in the context of 
the major histocompatibility complex (MHC). Two MHC-types can be distinguished: 
MHC class I and II. Their allelic variability is high. In humans the two MHC types are 
called HLA-types; HLA-A, B and C correspond with MHC class I and HLA-D with 
MHC class II. The HLA-D can further be divided in HLA-DR, DQ and DP [148]. 
The MHC class I, present on almost every cell surface, binds peptides 8-11aa in 
length. These peptides represent intracellular antigens (ags) and reflect the current 
state of the cell. Upon viral infection viral proteins are synthesized and a proportion of 
them are ubiquitin-tagged, degraded by proteasomes [157, 158], transported into the 
endoplasmic reticulum (ER) through a transporter associated with antigen 
presentation (TAP) [159], loaded on a MHC class I complex and passed through the 
Golgi apparatus before reaching the cell surface. 
MHC class II complexes are found on antigen presenting cells (APCs) only. They 
bind peptides 12 to 20 aa in length. These peptides are derived from extra-cellular 
antigens, which are actively captured by APCs through receptor-mediated endocytosis 
or other pathways. The endocytosed ag is then degraded in an acidic vesicle by 
proteases [160]. Meanwhile, class II molecules are synthesized within the ER and 
transported through the Golgi/trans-Golgi apparatus into the cytosol. The MHC class 
II vesicle then fuses with the endosome vesicle [161]. Peptide is bound in the MHC 
class II groove based on its affinity and the mature complex is finally displayed onto 
the cell membrane  
The two different MHC classes are recognized by two different subsets of T-
lymphocytes. CD8 positive (CD8+) T-cells recognize MHC class I and monitor 
thereby the intracellular state of a cell. Once they recognize a non-self peptide, i.e. a 
viral peptide, they become activated and kill the cell. CD8+ cells are therefore called 
cytotoxic T-lymphocytes (CTLs) and the peptide inducing such a response is called 
CTL-epitope.  
CD4 positive (CD4+) cells recognize MHC class II. Since extra-cellular antigen, such 
as free virus, is best eliminated through antibodies, CD4+ cells stimulate B-cell 
growth and antibody production, via cytokine secretion. CTL activity can also be 
enhanced. For this support activity they have been named T-helper cells (TH).    
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Two major subsets of T-helper cells can be distinguished by their different cytokine 
secretion patterns. A T-helper cell 1 (TH1) response is characterized by the secretion 
of interferon-γ (IFN-γ), IL-2 and IL-12. IFN-γ secretion stimulates B-cells to release 
soluble IgG2a abs in mice and similar opsonic and complement fixing IgGs in men. 
They are also responsible for macrophage activation and the induction of delayed-
type hypersensitivity responses, in which CD8+ T-cells are activated to become 
CTLs. A T-helper cell 2 (TH2) response leads to secretion of IL-4, IL-5, IL-6 and IL-
10. Through them mainly B-cells are induced to produce secretory or circulating abs 
so that immune responses that depend on abs are activated. The different cytokine 
secretion patterns are antagonistic. Up-regulation of one type of response results in 
down-regulation of the other [162].  
 
Conventionally T-cell epitopes are identified experimentally by screening sets of 
highly overlapping peptides. Depending on the size of the antigen and the numbers of 
HLA-alleles that need to be analyzed this becomes a time and money consuming 
undertaking.  
Since peptide ligands of a certain MHC-molecule share chemically related amino 
acids in certain positions of their primary sequence “peptide motifs” for every MHC-
allele can be defined [163, 164]. This information was rapidly used to predict 
potential T-cell epitopes and founded the discipline of “immunoinformatics”, which is 
“the application of computational informatics to the study of immunological 
macromolecules” [165]. Currently, sequence-based and structural approaches to 
epitope prediction can be distinguished [164-166]. The latter attempt to predict MHC-
peptide binding de novo with no requirement of known and experimentally 
determined binding data [165]. These programs often use 3D methods or try to 
calculate thermodynamic properties of the MHC-peptide complex and are therefore 
computationally intense.  
Sequence-based programs instead are data driven and rely on sequence alignments of 
natural ligands or synthetic peptides [164]. Alignment of natural ligands derived from 
MHC-peptide complexes and analyzed through Edman degradation [163], pool 
sequencing [163] as well as tandem mass spectrometry [167] generate “natural ligand 
motifs” which give information about the natural peptide repertoire presented by a 
certain MHC molecule. In contrast to alignments of synthetic peptides found to bind 
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MHC molecules natural binding motifs are not only a result of MHC-peptide binding 
properties but also reflect features of the antigen processing machinery [164]. From 
the obtained alignments either a specific binding motif, in which only some, or a 
scoring matrix in which all amino acids are considered is generated [168]. Matrix 
based programs were found to be more accurate [165]. The majority predicts potential 
MHC class I epitopes. Class I epitope prediction is easier to achieve since the ligands 
are, mostly 9 aas, of defined length and contain stringent motifs [164, 168]. Variable 
length and degenerated motifs makes class II epitope prediction more difficult [169].  
1.3.3 Dendritic cells 
As mentioned above B- and T-cell responses are initiated and modulated by DCs. 
They do so either by directly interacting with B-cells or CTLs or indirectly through 
the CD4+ cells they are activating. DCs were first discovered in 1896 as Langerhans 
cells in the skin and other peripheral tissue. There, they sentinel and monitor pathogen 
entry. Humans have about 109 DCs in the body; besides human skin DCs can be 
found in small numbers in blood, lung, spleen, heart, kidney and the B-and T-cell 
areas of the tonsils [146]. In all these tissues DCs are present in their immature state 
ready to capture, take-up and process antigen. DCs encounter ag either by chance or 
they are recruited to the sites of inflammation and infection through inflammatory 
chemokines [170, 171]. Immature DCs can capture ag by (i) phagocytosis [172-174], 
(ii) macropinocytosis [175], a process in which large vesicles are formed that are able 
to sample the extra-cellular fluid and its solutes, and (iii) receptor-mediated 
endocytosis [175-178]. Ag capture is so efficient that picomolar to nanomolar 
concentrations are sufficient [175]. Once ag is captured, DCs start to mature. The ag 
itself provides the maturation signal. DC maturation can also be induced by 
granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4 [179, 180]. 
IL-10 instead suppresses DC maturation [181].  
DCs can process ag in two different ways to generate MHC Class I and II presented 
peptides and consequently activate both CD4+ and CD8+ T-lymphocytes.  
MHC Class II peptides are generated through the exogenous pathway as described 
above (1.3.2). However, in contrast to other APCs, DCs are extremely efficient in 
generating MHC class II peptide complexes, due to specialized, MHC class II rich 
compartments that are abundant in immature DCs [182].  
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To generate CTLs, DCs display MHC class I peptide complexes that are produced 
through either the exogenous or the endogenous pathway. If a DC is infected with a 
virus, i.e. influenza virus, viral proteins are synthesized and degraded as described 
(1.3.2). Once again DCs are best suited, since they constitutively express di-ubiquitin, 
which permits more efficient ag processing [183]. To eliminate viruses, which do not 
infect DCs, CTLs are primed through the exogenous pathway. This is also known as 
“cross-priming”[184].  
Decline of ag uptake and the start of ag processing and presentation indicates the 
differentiation of DCs from their immature to their mature state. Besides differential 
expression of molecular markers, DCs also change their shape and location. DCs in 
peripheral tissue are of compact shape, which is maintained by actin cables. Upon 
maturation they migrate into the T-cell areas of lymphoid organs. Now they extend 
large, fine veils in many directions; a shape that is best suited for B- and T-cell 
interaction [185].  
It was estimated that one DC is able to activate 100-3000 T-cells [146]. This potency 
is not due to a single molecular factor but rather to the creation of a microenvironment 
in which T-cell immunity develops well due to (i) a 10 to 100 times enhanced MHC 
class I and II expression and presentation compared to other APCs [186], (ii) secretion 
of IL-12, which is an enhancer of both innate and acquired immunity [187], (iii) 
expression of accessory surface molecules which interact with their receptors on T-
cells to improve adhesion and communication with the harboring DC [188]. Not 
surprisingly DCs have been recognized as important targets for vaccine development, 
since they act as “nature’s adjuvant” [146, 189-191]. 
1.3.4 Epitope-based vaccines 
As seen above (viral) immunity is conferred through the specific recognition of 
epitopes by the humoral (1.3.1) or cellular (1.3.2) arms of the immune system, which 
are both controlled by DCs (1.3.3). Many of these small linear or structural peptides 
have been identified, mapped and their role in the establishment of immunity has been 
analyzed. Furthermore, mimotopes can be generated via “reverse vaccinology” (1.3.1) 
and new potential T-cell epitopes can be predicted in silico (1.3.2). Based on this 
knowledge and technologies is the concept of epitope-based or peptide vaccines.  
Traditionally, antiviral vaccines try to be as similar as possible to the naturally, 
occurring form of the pathogen, but without causing disease or other side effects. The 
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virus is rendered non- or weakly pathogenic through killing, inactivation or 
attenuation. Also subunits of the pathogen can be produced and combined to a vaccine 
[192]. All these approaches, as successful as they have been in the last decades, have 
considerable drawbacks, especially safety risks and difficult production.    
Epitope-based vaccines could circumvent some of those drawbacks by eliciting an 
immune response against a specific peptide, which makes them safe. Furthermore 
there are easily and cost-efficiently produced. However, the gain of safety, control 
and producibility goes hand in hand with loss of immunogenicity. This is due to (i) 
rapid peptide degradation, (ii) the flexible shape of unconstrained peptides and (iii) 
missing additional signals, i.e. T-helper cell support. It is also clear that any single 
epitope based vaccine will not be effective in a broad spectrum of the population since 
at least T-cell epitopes are restricted to certain HLA types. However, the latter can be 
overcome by creating a defined epitope cocktail, able to elicit cellular and humoral 
response [193] as well as to cover the most frequent HLA types in a population. The 
first can be overcome through adequate epitope presentation and delivery [192, 194]. 
Various systems are currently under investigation including: (i) chemical or genetical 
conjugation of peptides to larger proteins i.e. tetanus or diphtheria toxoid [195], (ii) 
creation of a multiple antigen peptide [196], polypeptides [197] or lipopeptides [198, 
199] (iii) incorporation of peptides and protein fragments within a liposome or 
immunostimulating complex (ISCOM) [129, 200] or virosome [128, 201] and the 
presentation on the surface of recombinant phages [202, 203], animal or plant viruses  
(1.1). 
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1.4 Objectives 
Alfalfa mosaic virus, a plant virus, was used to screen the RSV F protein to identify 
potential B and T cell epitopes that could be used to develop a vaccine against this 
pathogen. To achieve this, a number of peptides derived from RSV-F were fused to 
the N-terminus of AlMV coat protein subunits and consequently displayed on the 
surface of AlMV particles. The performance of all constructs was analyzed, virus 
particles isolated, and immunological analysis carried out. Attempts were made to 
increase the efficiency of the expression system by minor modification of the 
constructs. 
Peptides that were displayed included (i) an RSV-F derived antigen fragment library, 
that consisted of 34 overlapping peptides that scanned the whole F protein (ii) peptide 
mimics selected against the neutralizing antibody HNK20 (iii) fusion-inhibition 
peptide T-118, that could be used as antiviral peptide drugs.  
Immunological analysis included, (i) mice immunization and (ii) T-helper cell epitope 
screening using human dendritic cells.  
Furthermore data obtained from the T-helper cell epitope screen were compared with 
those generated by three different epitope prediction programs to evaluate their 
capacity to predict T-helper cell epitopes in silico.  
You know my methods, Watson!
Sir Arthur Conan Doyle
2 Materials and Methods 
This section follows the flow of my research. It is grouped into four main parts: (i) 
recombinant DNA techniques used to construct the different pBR-plasmids (ii) plant 
viral vector techniques used to analyze and produce pBR-constructs in plants (iii) 
phage display techniques used to develop a HNK20 mimotope and (iv) immuno-
logical methods used to evaluate the immunogenic properties of constructs produced.  
2.1 General remarks 
2.1.1 Buffers, media and solutions  
All buffers, media and solutions were prepared according to standard protocols, as 
described [204]. Where relevant, specific solutions or buffers have been described. 
Media for bacterial cultivation was sterilized by autoclaving (25 min/121°C/2 bar). 
Thermolabile components were filter sterilized by passing through a 0.2 µm filter and 
added to the autoclaved media or buffer after they were cooled down to 50°C.  
2.1.2 Enzymes and kits 
Restriction enzymes, T4 DNA-ligase from New England Biolabs (NEB), Beverly, 
MA, were used for DNA digestion and ligation, respectively. PCR Supermix High 
Fidelity (Invitrogen, Carlsbad, CA) was used for PCR amplification. DNA Taq 
polymerase from NEB was used for identification of colonies that contained 
recombinant DNA by PCR. The following kits were used: 
Rapid PCR purification system (Marligen Biosciences, Ijamsville, MD) 
Rapid plasmid miniprep system (Marligen Biosciences, Ijamsville MD) 
AmplicapTM, T7 High yield Massage Maker Kit (Epicenter, Madison, WI) 
Ph.D.C7C and Ph.D. 12 Phage display Library kit (NEB Inc. Beverly, MA) 
2.1.3 Equipment 
1. Blender: “Heavy duty laboratory blender” (Waring Laboratory) 
2. Camera: KodakDC 290 digital (Eastman Kodak Company, New Haven, CT).  
3. Centrifuges: AvantiTM 30, AvantiTMJ-20XPI (Beckman Coulter, Fullerton, CA) 
and OptimaTM XL-100k Ultracentrifuge (Beckman Instruments Inc, Palo Alto, 
CA), Sorvall Biofuge Fresco (Kendro Laboratory Products, Ashville, NJ) Rotors: 
30                                                                                                                          2 Materials and Methods 
JLA 10.500, JLA 9.100 and JA 25.50, JA 12, 70Ti rotor with “Quick-Seal”TM 
ultra-centrifugation tube (Beckman Instruments Inc, Palo Alto, CA). 
4. DNA gel electrophoresis apparatus: wide mini and mini cells for DNA agarose 
electrophoresis (USA Scientific), and the power suppliers (USA Scientific). 
5. InnovaTM 4340 incubator shaker (New Brunswick Scientific). 
6. PCR Thermocyclers: Primus and Primus 96 plus (MWG). 
7. Photometer: Spectra Max Plus 384 (Molecular Devices, Sunnyvale, CA) 
8. Protein gel electrophoresis equipment: Mini PROTEAN IITM from BioRad.  
9. Scanner: HP Scanject 7400c (Hewlett Packard Co., Palo Alto, CA) 
10. Semi-dry transfer apparatus for Western blots (Hoefer Scientific) 
11. UV-Transilluminators: wavelength 302nm and UVT-20M (Herolab). UV-
chamber (Bio-Rad). 
2.2 Recombinant DNA techniques 
All cloning and cell transformations were performed according to Sambrook et al. 
(2001) [204]. Escherichia coli DH5α competent cells (Life Technologies, 
Gaithersburg, MD) were used for transformation, ER2738 cells (NEB) were used for 
phage amplification. Details of primers can be found in the appendix (7.3).   
2.2.1 Plasmid construction 
2.2.1.1 Construction of pBR-RSV-F-1/2/3....33/34 
An RSV-F cDNA clone was kindly provided by Dr. Peter Collins (NIH, Bethesda, 
MD) [1]. RSV-F forward and reverse peptide primers were designed using the human 
RSV strain A2 F-protein sequence (Genebank ACCESSION X02221, gi 61210) [2]. 
Every forward primer started 5’ with CGG followed by a KpnI site (GGTACC), the 
first two AlMV CP codons (ATG AGT) and 15 bp of the RSV-F-sequence (Table 
7-2). Every reverse primer ended with 15bp of the RSV-F-sequence followed by a 
SalI site (GTCGAC) and an additional CGG (Table 7-2). The first RSV-F peptide 
started at position aa21/bp64 and ended at aa45/bp135 (aa and bp are counted 
including the first methionin, the start codon); RSV-F-2 started at aa38/bp112 to 
aa61/bp183, RSV-F-3 from aa54/bp160 to aa77/bp231, until RSV-F-34 aa550/bp1648 
to aa573/bp1719. All 34 inserts were PCR amplified (15 seconds (’’) 94°C 
denaturation, 30’’72°C amplification and 15’’15°C (5x), 15’’25°C (5x), 15’’35°C 
(5x), 15’’45°C (5x) and 15’’55°C (20x) annealing).  
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The resulting PCR-products were columne purified, KpnI and then SalI-digested, re-
purified and ligated into similarly digested pBR using T4 DNA ligase. Chemical 
competent DH5α cells were heat shock transformed and plated on selective agar 
plates containing 100 µg/ml ampicillin. Selected clones were verified by PCR [3] 
using vector- or insert-specific primers (Table 7-8). Positive clones were inoculated 
into 2ml LB-amp and grown overnight at 37oC. Plasmid DNA was extracted and 
DNA concentration was determined based on the absorbance at 260nm.  
2.2.1.2 Construction of pBR-RSV-F-bis, -SSQ and –DE, HR2 and T118  
The pBR-RSV-F-bis as well as pBR-RSV-F-HR2 and pBR-RSV-F-T118 constructs 
were generated as in 2.2.1.1. Primer details are given in Table 7-3. The resulting 
peptides/inserts corresponded to aa110-131 (6bis), aa210-233 (12bis), aa273-292 
(16bis), aa282-299 (17bis), aa299-326 (18bis), aa403-426 (24bis), aa414-426 (25bis), 
aa474-524 (HR2) and aa488-522 (118).  
To generate pBR-RSV-F-18 SSQ and 18bis SSQ three codons (TCT TCT CAA) were 
added after ATG AGT to the 5’ RSV-F-18 and 5’ RSV-F-18bis forward primers and 
named 5’RSV-F-18 SSQ, and 5’ RSV-F-18bis SSQ. For PCR amplification 5’ RSV-
F-18 SSQ was used with 3’ RSV-F-18 and 5’ RSV-F-18bis SSQ with 3’ RSV-F-18bis 
(Table 7-4).  
For the pBR-RSV-F-DE constructs 2 codons (GAT GAA) were added after ATG 
AGT to the 5’ RSV-F-24bis forward primer, to add DE 5’ of the peptide sequence and 
generate RSV-F-DE 24bis, and before the SmaI site (GTCGAC) of the 3’ RSV-F-
24bis reverse primer, to add DE 3’ of the peptide sequence and generate RSV-F-24bis 
DE. When used in combination RSV-F-DE24bisDE was generated (Table 7-5). 
All PCR fragments generated were then treated as described in 2.2.1.1 
2.2.1.3 Construction of pBR-RSV-F-25bis, LTL, ETE, pBR-H7A2, H12H2 
pBR-RSV-F-25bis LTL and ETE were generated using the overlapping primers 5’+3’ 
25bis LTL, 5’+3’ 25bis KTK (Table 7-6). The HNK20 mimics H7A2 and H12H2 
were assembled using primers specific for H7A2 and H12H2 (Table 7-7). 45µl PCR 
Supermix High Fidelity (Invitrogen, Carlsbad, CA) and 2.5ul of each 5’ and 3’ primer 
(100µM) were mixed and an assembly PCR performed [15”94°C; 1 minute (’) 4°C, 1’ 
72°C (4x), 10” 94°C 30” 30°C, 30” 72°C (15x), 1’ 72°C ]. The obtained PCR 
fragments were then treated as described in 2.2.1.1.  
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2.2.2 DNA Sequencing 
Column purified plasmid mini prep DNA from 2.2.1.1, 2.2.1.2 and 2.2.1.3 at a 
concentration of 50 to 75ng/µl in dH2O and sequencing primers (Table 7-8) at a 
concentration of 1.6-2µM were provided to Brewster F. Kingham (University of 
Delaware, College of Agriculture and Natural Resources, Charles C. Allen 
Biotechnology Laboratory, DNA Sequencing Facility). Sequencing reactions were 
carried out with AmpliTaqTM DNA Polymerase FS dye terminator cycle sequencing 
chemistry using the ‘ABI PRISM BigDye Terminator Cycle Sequencing Ready 
Reaction Kit’ (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
protocol. Reaction mixes were subjected to 25 cycles in an Applied Biosystems 
GeneAmp 9700 thermal cycler. Each cycle consisted of 10’’ 95°C, 5’’ 50°C and 4’ 
60°C. For sequencing an automated ABI-Prism 377 DNA Sequencer (Applied 
Biosystems, Foster City, CA) was used. Sequencing data were evaluated using 
Chromas, Version1.51 (Technelysium) and SeqMan/Lasergene (DNASTAR, 
Madison, WI). 
2.2.3 Peptide and Protein analysis 
Physio-chemical properties of RSV-F derived or other peptides as well as those of 
resulting chimeric AlMV-CP proteins were determined using EditSeqTM Expert 
Sequence analysis software (DNASTAR, Inc). The incorporated algorithms allowed 
the direct calculation of molecular weight, length, charge and pI. Furthermore it 
determined the number of strongly basic (K, R), acidic (D, E), hydrophobic (A, I, L, 
F, W, V) and polar (N, C, S, Q, T, Y) aas. Peptides were considered hydrophobic if 
they contained more hydrophobic then polar aas and vice versa.  
2.2.4 In vitro transcription  
All pBR constructs (2.2.1.1, 2.2.1.2, 2.2.1.3) and pBR without insert as an RNA3 
control were SmaI linearized over night (o.n.) at 25°C, cleaned and eluted in 50µl of 
dH2O. 2µl of DNA were run on a 1% (w/v) agarose gel to determine linearization 
efficiency. DNA concentration was calculated based on the absorbance at 260nm.  
Linearized construct were transcribed using AmplicapTM, T7 High yield Message 
Maker Kit (Epicenter, Madison, WI) according to the manufacturer’s instructions. 
The transcription reaction was incubated at 37°C for 3h. 2µl of the reaction was 
analyzed on a 1% (w/v) agarose gel to determine transcription efficiency.  
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2.3 Plant viral vector techniques 
2.3.1 Plant inoculation 
All BR-RSV-F constructs were analyzed and produced in transgenic Nicotiana 
tabacum cv. Samsun NN plants expressing the AlMV P1 and P2 (P12) replicase genes 
[49]. All P12 plants were grown and maintained in a controlled BL2P greenhouse. 
Plants were grown to a 3 to 4 leave stage, approximately 6 weeks after seeding, at a 
temperature between 19 and 22°C, ambient humidity and 12h day/night cycles.  
A 20µL transcription reaction (2.2.4) was mixed with 1 volume of FES (sodium-
pyrophosphate 1% (w/v), macaloid 1% (w/v), glycine 0.5 M, K2HPO4 0.3M, pH 8.5, 
with phosphoric acid) and 2 volumes of ddH2O to generate the inoculum.  
Two major leaves were dusted with Carborundum (400grit, ScholARTM Chemistry, 
Aldon Corp. Avon, NY). 4 µl inoculum per leaf was applied by gentle rubbing. 
Transcripts of RNA3 were used as AlMV wt control. ddH2O was used as a mock 
control. At least 3 plants were inoculated per construct.  
2 samples of inoculated (i) and non-inoculated (n) leaves were taken at 4, 7, 10 and 14 
days post-inoculation (dpi) using an Eppendorf tube lid to cut out leaf discs.  Samples 
were prepared for Western analysis (2.3.4). Symptom formation was documented the 
same days using a digital camera. 
For large scale virus purification one transcription reaction (20µl) was mixed with 1 
volume of FES and 2 volumes of ddH2O and used as inoculum for 15 plants. All 
major leaves were inoculated. Leaves were harvested after 4 to 7 dpi depending on the 
construct, weighed and either frozen at –80° or processed immediately (2.3.2).   
2.3.2 Virus Purification 
Harvested leaves were ground for 1 min in 3 volumes of extraction buffer (0.1M Na-
PO4, pH 7.1, 0.1% (v/v) Triton X-100, 2.5 mM EDTA, 2.5 mM 
Diethyldithiocarbamate (DEDTC), 1mM β-Mercaptoethanol, 1% (w/v) 
Polyvinylpolypyrrolidone (PVPP) using a Heavy duty laboratory blender (Waring 
Laboratory). The obtained homogenate was centrifuged for 30min at 15,000g, 4°C. 
The supernatant was filtered through Miracloth (Calbiochem, EMD Biosciences Inc., 
San Diego). Virus was precipitated with 5% (w/v) polyethylene glycol (M.W. 
20,000;Sigma) at 4°C for 2.5h under constant stirring. The precipitate was collected 
by centrifugation at 15,000g for 30min at 4°C. The resulting pellet was resuspended 
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in 30 ml of re-suspension buffer (0.1M Na-PO4, pH 7.1, 2.5 mM EDTA). The 
suspension was transferred into a 50 ml Falcon tube (Beckton, Dickson and Company, 
Franklin Lakes, NJ) and centrifuged for 30 min at 8000g, 4°C to remove insoluble 
material. The supernatant was transferred into an Oak Ridge centrifugation tube and 
stored at –80°C until enough samples were available for ultracentrifugation. Prior to 
ultracentrifugation, tubes were slowly thawed in cold water and the solution clarified 
by centrifugation (30min, 30,000g, 4°C). Supernatants were transferred into ultra-
centrifugation tubes, filled up with re-suspension buffer, sealed and ultra-centrifuged 
for 2h at 60,000 rpm in a Ti70 rotor at 4°C. The pellet was resuspended in 2 to 6 ml of 
final buffer (0.01 M Na-PO4, pH 7.1, 30 mM EDTA) and transferred into 2ml 
Eppendorf tubes. The suspension was incubated o.n. at 4°C with constant rotation. 
The suspension was spun down in a refrigerated (4°C) tabletop centrifuge at 13,000 
rpm for 20 min to clarify. Total protein concentration was determined by Bradford 
assay (2.3.5) and the purity of the preparation analyzed by SDS-PAGE followed by 
Coomassie staining (2.3.4). Finally, virus concentration was adjusted to 0.5, 1, or 2 
mg/ml using final buffer, filter sterilized and aliquoted (0.45 µm filter; Nalgene, Nalg 
Nunc International, Rochester, NY).  
2.3.3 Plant sample preparation 
Plant samples (2.3.1) were ground in 200 µl (100 µl per leaf disc) of Bradley Buffer 
(50 mM Tris pH 7.5, 10 mM KCl, 5 mM MgCl2, 0.4 M Sucrose, 20% (v/v) Glycerol, 
1 mM DTT fresh) using an electrical mini drill and sterilized plastic pestles 
(Craftsman Minitools, Sears Hardware Store, Newark, DE). 50µl of 5x protein sample 
buffer (250 mM Tris-Cl, pH 6.8, 500 mM dithiothreitol, 10 % (w/v) SDS 
electrophoresis grade, 0.5% (w/v) bromophenol blue, 50% (w/v) glycerol) was added 
and samples boiled for 5 min before separation by SDS-PAGE (2.3.4) 
2.3.4 SDS-PAGE, Coomassie staining and Western blot analysis 
Whole plant proteins (2.3.3) or purified virus (2.3.2) were separated on 12.5% SDS-
PAGE [205] and either electro-blotted onto an ImmobilonTM-P transfer membrane 
(PVDF) (0.45 µm, Millipore), for 1h at 100 mA per gel using a semi-dry transfer 
apparatus (Hoefer Scientific) or stained using Coomassie brilliant blue (Pierce  
Biotechnology). After blocking the membrane o.n. in PBS containing 5% (w/v) non-
fat dry milk (Super G Inc., Landover, MD) proteins were allowed to react with an 
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anti-AlMV-CP alkaline phosphatase-coupled antibody (1:2000 in PBS, Agdia, 
Elkhart, IN) for at least 1h, washed three times in 1X PBST, and detected using 
BCIP/NBT as substrate (Sigma Aldrich Co., St. Louis, MO). Gels and blots were 
scanned for further analysis and documentation. Purity of the recombinant CP was 
determined by densitometric analysis using KODAK 1D 3.5 software (Eastman 
Kodak Company, New Haven, CT). 
2.3.5 Quantification of total soluble proteins by Bradford assay 
Purified virus and a known concentration of BSA as standard were diluted in final 
buffer or PBS. 10 µl of each dilution was transferred into wells of a low-protein-
binding 96-well microtiter plate (Nalge Nunc International, Rochester, NY). 10 µl of 
the buffer was used as a blank. 300 µl of Coomassie Plus Protein Assay Reagent 
(Pierce Biotechnology) were added to each well, mixed with the proteins and 
incubated at RT for 10 min followed by the measurement of OD595 and the data 
acquired via SOFTmax Pro (Molecular Devices). For each dilution, measurements 
were performed in triplicate and values averaged.     
2.4 Phage display 
2.4.1 Panning procedure 
The HNK20 monoclonal ab, kindly provided by Dr. Farshad Guirakhoo (Acambis, 
Cambridge, MA) [114, 206] was diluted to 100 µg/ml in PBS.  Per library (Ph.D.C7C 
or Ph.D. 12; NEB Inc. Beverly, MA), 4 flat bottom microtiter plates (NuncTM, Nalge 
Nunc International, Rochester, NY) were coated with 150 µl of antibody solution for 
3 to 4 h at 37°C in a humidified container. The coating solution was poured off and 
the plate firmly slapped onto a clean paper towel to remove residual solution. The 
wells were blocked with 350 µl I-block (Topix, Bedford, MA) solution at 4°C o.n.  
The blocking solution was discarded as described above and plates washed 6 times 
with PBST. 2x1011 phages per library were diluted in 100 µl of I-block per well and 
pipetted into coated wells. The plate was incubated and gently rocked for 2-3 h at RT 
in a humidified container. Non-binding phage were discarded by pouring of the phage 
solution and tapping the plate face-down onto a clean paper towel. Wells were washed 
9 times with PBST as described above. A fresh paper towel was used for every 
tapping to prevent cross-contamination.  
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Bound phage was eluted with (100 µl/well) glycine-HCl (0.2M, pH 2.2) and gentle 
rocking for no longer than 10 min. The eluate was transferred into a micro-centrifuge 
tube and neutralized with 15 µl Tris-HCl (1M, pH 9.1) per 100 µl. The eluate was 
titered (2.4.2) and amplified (2.4.3).  
2.4.2 Phage titering 
10ml LB, containing tetracycline (20µg/ml), were inoculated 1:100 with an E. coli 
ER2738 master-culture and grown until mid-log phase (OD600 ~ 0.5). LB/IPTG/Xgal 
plates were warmed up at 37°C for at least 3h. While cells were growing, top agar 
(0.7 % w/v) was melted and dispensed in 3ml sterile culture tubes, one per expected 
phage dilution. Tubes were held at 50°C until ready for use. 10-fold serial dilutions of 
eluted (2.4.1) or amplified (2.4.3) phages were made in LB. Eluted phage were 
analyzed at a dilution of 10-1 to 10-4, amplified phage at 10-8 to 10-11. Once culture had 
reached mid-log phase 200 µl were aliquoted into microfuge tubes. 10 µl of phage 
dilution was added, vortexed quickly and incubated at RT for 1 to 5 min. One at a 
time, the infected cells were transferred to the culture tube containing top agar held at 
50°C. The tube was vortexed quickly and poured immediately onto pre-warmed 
LB/IPTG/Xgal plate spreading the top agar evenly by tilting the plate. Plates were 
cooled down for 5 min, inverted and incubated o.n. at 37°C. Plates were inspected the 
next morning and those having ~ 102 plaques counted. Plaque forming units (pfu) per 
10 µl were calculated multiplying the pfu-number by the dilution factor.  
2.4.3 Phage amplification 
2.4.3.1 Small-scale amplification 
To amplify eluted phage (2.4.1) 25ml 2xYT, containing tetracycline (20µg/ml), were 
inoculated 1:100 with an E. coli ER2738 master-culture and the eluate from 2.4.1. 
The culture was incubated for 4.5 to 6h at 37°C under vigorous shaking and then 
transferred into an Oak Ridge tube. Cells were pelleted for 20min at 48,500xg and 
4°C. The supernatant was transferred into a new Oak Ridge tube and phage was 
precipitated with 1/6 volume of PEG/NaCl (20% (w/v) polyethylene glycol (MW 
8000), 2.5M NaCl) at 4°C and continuous rotation o.n. The precipitate was collected 
after centrifugation for 20 min at 48,500xg and 4°C, the supernatant decanted, and 
residual liquid removed. The white pellet obtained was re-suspended in 1ml PBS and 
transferred into a micro-centrifuge tube. Residual cells were removed by spinning for 
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5 min in a refrigerated tabletop centrifuge at (13,000g) maximum speed for 20 min. 
The supernatant was transferred into another micro-centrifuge tube and the phage 
precipitated by adding 1/6 volume PEG/NaCl and incubating the mixture on ice for at 
least one hour. Precipitate was collected after centrifugation for 10 min, 4°C at 
(13,000g) maximum speed in a refrigerated tabletop centrifuge, the supernatant 
decanted, and remaining liquid removed. The pellet was suspended in 1 ml of PBS, 
0.02%NaN3. The amplificate was titrated (2.4.2) and used in another round of panning 
(2.4.1).       
2.4.3.2 Large-scale preparation and CsCl purification of phage 
To obtain larger quantities of phage for mice immunization the clones H7A2 and 
H12H2 as well as the libraries Ph.D.C7C and Ph.D.12 were amplified and CsCl 
gradient purified according to Bonnycastle et al. (2001) [207].  
2.4.3.2.1 Large scale preparation 
Briefly, a single H7A2 and H12H2 plaque was picked from a titration plate and 
transferred into a 1.5ml micro-centrifuge tube containing 1ml 2xYT medium and 
tetracycline (20µg/ml). After vortexing 100 µl were used to inoculate two 2-liter 
flasks containing 500 ml of 2xYT and 15µg/ml tetracycline. The flasks were 
incubated for ~ 20h at 37°C and vigorous shaking (225rpm). For the amplification of 
Ph.D.C7C and Ph.D.12 a single ER2738 colony was picked from a master-plate to 
inoculate a 10 ml overnight culture. 2.5 ml of the overnight culture together with 10 
µl of each library was used as inoculum. Cultures were grown as above.  
Cells were pelleted through centrifugation at 2400xg for 10min at 4°C and the 
supernatant re-centrifuged at 6200xg for 10 min at 4°C. The supernatant was than 
transferred into a screw-cap bottle and the phage was precipitated by adding 1/6 
volume PEG/NaCl to the bottle and shaking it gently at 4°C o.n. Phage was collected 
by centrifugation at 6200xg for 40 min at 4°C. Supernatant was discarded and residual 
liquid removed. Phage pellet was dissolved in 15 ml TBS (50 mM TrisHCl, 150 mM 
NaCl, pH 7.5) by shaking at 150 rpm in 37°C for 30 min. The phage solution was 
transferred into an Oak Ridge tube. Tubes were centrifuged at 22,500xg for 10 min at 
4°C to clear the supernatant, before transferring it into a fresh Oak Ridge tube. Phages 
were again PEG/NaCl precipitated and collected by centrifugation at 10,100g for 40 
min at 4°C. Supernatant was removed as described, the pellet dissolved in 10 ml of 
TBS and the solution cleared by centrifugation at 22,500g for 10 min, 4°C.  
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2.4.3.2.2 CsCl purification 
30 ml of a 31% (w/w) CsCl solution (in TBS) was prepared with the 10ml TBS that 
contained the phage (2.4.3.2.1). The solution was transferred into a “Quick-Seal”TM 
centrifugation tube (Beckman Instruments Inc, Palo Alto, CA) and filled up with CsCl 
solution if necessary. The tubes were sealed, transferred into a 70Ti rotor and spun in 
an OptimaTM XL-100k ultracentrifuge for 27h at 54,800rpm and 4°C. The phage band 
was removed as described in [204] using a syringe. To remove CsCl the extracted 
band was transferred into an Oak Ridge tube, mixed with 20ml TBS and transferred 
again into a “Quick-Seal”TM centrifugation tube. The tube was filled with TBS, sealed 
and ultra-centrifuged for 4h at 50,000 rpm (251,720xg) and 4°C.  The pellet was 
dissolved in 4ml TBS containing 0.02% (w/v) NaN3. Phage concentration was 
determined spectrophotometrically (2.4.3.2.3) and phage stored at 4°C protected from 
light.  
2.4.3.2.3 Spectrophotometric quantitation of phage 
Phage concentration was determined by spectrophotometric estimation as described in 
[207]. Briefly, phage was diluted in TBS and scanned from 240 to 320 nm with an 
UV spectrophotometer. The absorbance at 269nm and 320nm was measured and the 
“adjusted” A269-basline calculated as: A269-adjusted = A269 – A320.  
The virion concentration in phage particles per ml was calculated as: 
 A269-adjusted x 6 x 1016 / number of nucleotides of the phage genome (6407bp). 
2.4.4 Preparation of phage DNA for sequencing 
12 clones per library showing good binding characteristics (2.4.5.1) were selected and 
amplified in 3 ml of an ER2738 culture (2.4.3). For the preparation of single stranded 
phage DNA a “Qiagen Spin M13” kit (Qiagen Inc., Valencia, CA) was used. 
Obtained DNA was quantified by DNA gel electrophoresis and OD260 measurements. 
Aliquots at a concentration of 65 ng/µl were sent for sequencing (2.2.2) using the 
sequencing primer –96gIII (Table 7-8). 
2.4.5 Phage ELISAs 
To select high affinity binders prior to sequencing and to characterize different clones 
after sequencing, phage ELISAs were performed. Two selected clones (H7A2, 
H12H2) were also tested in an RSV/phage competition ELISA.    
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2.4.5.1 Selection of high affinity binders for sequencing 
2.4.5.1.1 Preparing a phage master-plate 
Before performing the phage ELISA a phage master-plate was established for further 
use. 200 µl of a mid-log ER2738 culture were dispensed per well of a 96-well conical 
bottom plate (NuncTM, Nalge Nunc International, Rochester, NY). 40 individual 
plaques from the titration plates (2.4.2) of the third round of amplification (2.4.3) and 
the fourth elution (2.4.1) were transferred with a sterile toothpick onto the master-
plate. As controls dH2O, medium and medium with ER2738 were used.  To amplify 
the phage the plate was incubated at 37°C with shaking for at least 4.5-6h or o.n. 
Another 96 well plate containing 250 µl of ER2738 cell suspension per well and the 
controls was inoculated with 5 µl from the master-plate and amplified o.n. The next 
day the phage amplification plate was centrifuged at maximum speed in a suitable 
rotor to pellet cells. 150 µl of the phage-containing supernatant was mixed with 150 
µl of 2x I-block in a 96 well plate.   
2.4.5.1.2 HNK20 capture ELISA 
An ELISA plate was coated with HNK20 (100 µl/well, 100 µg/ml) and blocked with 
I-block o.n. at 4°C (2.4.1). Another plate was coated with a random IgG to exclude 
phages, which might have been selected due to the binding to other parts of the 
antibody, such as the Fc. 100 µl of phage/I-block mixture (2.4.5.1.1) was transferred 
onto the ELISA plate and incubated for 2-3h at RT on a plate shaker. After washing 3 
times with PBST, 100 µl of horseradish peroxidase (HRP)-conjugated anti-M13 
antibody (1:5,000 dilution in blocking buffer, Pharmacia) was added per well and 
incubated for 1 to 2 h at RT on a plate shaker. The antibody solution was then 
discarded and the plate washed 3 times with PBST. The plates were developed for 20 
min using o-phenylediamine (OPD; Epicenter, Madison, WI) as a substrate. The 
reaction was stopped with 50 µl of 5 M H2SO4 and read at 490nm in a plate reader. 
2.4.5.2 Phage titration against HNK20 
After sequencing (2.2.2) 6 different peptide motifs were identified corresponding to 
clones H7A2, H7A4, H12B3, H12C2, H12D3 and H12H2. The clones were amplified 
(2.4.3) and used for phage titration against HNK20. Serial dilutions of the phages in I-
block were used for HNK20 capture ELISAs as described above (2.4.5.1.2). The 
amplified libraries Ph.D.C7C and Ph.D.12 were used as controls.  
40                                                                                                                          2 Materials and Methods 
2.4.5.3 Competition ELISAs 
To determine whether or not H7A2 and H12H2 competed with RSV-F protein for 
binding to HNK20, a competition ELISA was performed. Purified RSV, Long Strain 
(Biodesign, Saco, Maine) at starting amounts of 10, 5 or 2.5 µg was serially diluted in 
90 µl of I-block. 10µl of phage (2.4.5.2), giving an OD490 of ~ 1 was added to each 
RSV dilution and mixed. As control for RSV, wt AlMV (1 µg/well) was used and 
prepared. As control for H7A2 and H12H2, the amplified phage libraries Ph.D.C7C 
and Ph.D.12 were used. 100 µl of each mixture was transferred onto an ELISA plate 
coated with 0.1 µg/well HNK20 and blocked with I-block. The ELISA was then 
developed and read as described above (2.4.5.1.2).  
2.4.5.4 AlMV-H7A2 and H12H2 ELISA 
To determine if the AlMV CP fusion peptides H7A2 and H12H2 (2.2.1.3, 2.3.2) had 
the same binding properties as phage-presented peptides, they were tested in an 
HNK20 ELISA (2.4.5.1.2). Serial dilutions of purified wt AlMV, -H7A2 and -H12H2 
were made in I-block starting at 100 ng/µl. 100 µl of each dilution was transferred to 
HNK20 coated and blocked ELISA plate and incubated for 4h at RT. After 
incubation, the solutions were discarded and the plate washed 3 times with PBST. 100 
µl of an anti-AlMV CP HRP-labeled antibody (Agdia, Elkhart, IN) at 1:2000 in I-
block was added and the plate incubated for 1h at RT. The plate was developed after 
adding OPD, and read at 490nm. 
2.4.6 Phage Western blots 
Obtained phages H7A2 and H12H2 (2.4.3) as well as AlMV-H7A2 and -H12H2 
(2.2.1.3, 2.3.2) were run on a 12.5% (w/v) SDS-PAGE gel and electro-blotted onto an 
Immobilon-P membrane. The membrane was blocked with I-block o.n. at 4°C. The 
membrane was incubated in a 1:10,000 dilution of HNK20 (0.1 µg/ml) for 2h at RT. 
The solution was discarded and the membrane washed 3 times with PBST. Secondary 
anti-mouse IgA (1:2500; Sigma, St.Louis, MO) was added and incubated for 1h at 
RT. After incubating the membranes with BCIP/NBT, they were developed and 
analyzed.     
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2.5 Immunological Methods 
2.5.1 Immunization of mice 
Mice immunization was performed with Frank Warren (Office of Laboratory Animal 
Medicine, University of Delaware). Four eight week old Balb/C female mice (Harlan 
Sprague Dawley Inc., Indianapolis Indiana) were injected intraperitoneally and 
subcutaneously three times at 2 week-intervals with purified particles of AlMV-RSV-
F-9-12, 14-16, 19-22, 26, 27,or 29-31 (100 µg per injection), in the presence of 
Freund’s complete (first injection) or incomplete (second injection) adjuvant (Sigma, 
St. Louis, MO). Control groups received AlMV particles (100 µg per injection), Final 
buffer, or inactivated RSV (5 µg/per injection). AlMV-RSV-F-9, AlMV or inactivated 
RSV were also injected without any adjuvant.  
To test the immunogenicity of the Hnk20 mimic three mice were injected with H7A2 
(4.2 x 1012 particles per injection) or H12H2 (5 x 1012 particles per injection) per 
construct as described above. Amplified libraries Ph.D. C7C and Ph.D. 12 at the 
corresponding concentration were used as controls.  
Serum samples were collected on days 0, 14, 28 and 42 through eye-bleeding using 
non-heparinized needles. Sera were analyzed in an RSV-ELISA (2.5.1.1).  
2.5.1.1 RSV ELISAs 
Purified RSV (Hytest, Turku, Finnland) was diluted to 2.5 µg/ml in PBS. 100 µl were 
used per well to coat ELISA plates that were then incubated at 37°C for 3h. Plates 
were blocked with 300 µl I-block o.n. at 4°C. Serial dilutions of sera (2.5.1) were 
made in I-block starting at a dilution of 1:50. 100 µl of each dilution was transferred 
onto the coated, 6 times PBST-washed ELISA plates. Plates were incubated on a plate 
shaker for 3 h at RT and washed 6 times with PBST using an automated plate washer 
(EMBLA, Skatron-Instruments/Molecular Device Corporation, Sunnyvale, CA). 
Plates were then incubated with HRP-labeled, goat anti-mouse IgG antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA) at 1:10,000 in PBS for 1h at 
RT. Plates were washed again 6 times and developed with 200 µl of OPD solution 
(Agdia, Elkhart, IN), stopped with 50 µl of H2SO4 and read at 490nm. 
Endpoint titers were reached if the signal was below the AlMV wt signal plus 2 times 
its S.D. 
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2.5.2 Generation of a T-helper de novo response 
2.5.2.1 Cells 
Human peripheral blood mononuclear cells (PBMC) used were separated from 
leukapheresis products of normal healthy donors by density gradient centrifugation in 
Lymphocyte Separation Medium (ICN Biomedicals Inc., Aurora, OH).  The cells 
were viably frozen in RPMI-1640 (Invitrogen Corp., Grand Island, NY) containing 
20% (v/v) human AB serum (Gemini Bio-Products, Woodland, CA) and 10% (v/v)  
DMSO (Sigma, St. Louis, MO). The cells were stored in the vapor phase of liquid 
nitrogen until used.  DNA was prepared form a portion of the cells using the QIAamp 
DNA MINI Kit (Qiagen, Valencia, CA). HLA A, B and DR locus typing was 
conducted using One Lambda Micro SSPtM ABDR Typing Kit (One Lambda Inc., 
Canoga Park, CA). This kit utilizes a DNA-based technique (PCR) for rapid, low to 
intermediate resolution typing.    
2.5.2.2 Pooling of AlMV-RSV-F constructs 
To allow screening of all available 22 AlMV-RSV-F constructs (2.2.1.1, 2.3.2), equal 
amounts (40 µg) of constructs were pooled in 7 groups. Pool A (AlMV-RSV-F-1/24), 
B (AlMV-RSV-F-3/4/5), C (AlMV-RSV-F-9/10/11), D (AlMV-RSV-F-14/15/16), E 
(AlMV-RSV-F-19/20/21/22), F (AlMV-RSV-F-26/27/28) and pool G (AlMV-RSV-
F-29/30/31). Each pool (besides A) presented a cluster of overlapping peptides. Final 
concentrations of individual peptides within the pools ranged from 0.166 mg/ml to 
0.333mg/ml, due to the different initial concentrations or each prep. AlMV-RNA-3 at 
a concentration of 0.2 mg/ml was used as control.  
2.5.2.3 T-helper de novo  responses to AlMV-RSV-F-constructs 
Cryopreserved PBMC were thawed at 37°C for 5 min., washed with complete RPMI 
(cRPMI; RPMI supplemented with 10% heat-inactivated human Ab serum (Gemini 
Bio-Products, Woodland, CA), 2% (v/v) 1 M Hepes Buffer solution (Invitrogen), 2 
mM L-glutamine (Invitrogen), 100 U/ml penicillin and 100 µg/ml streptomycin (both 
Invitrogen) and resuspended in cRPMI containing 13 ng/ml GM-CSF and 15 ng/ml Il-
4 (both from R&D Systems, Minneapolis MN). PBMC were plated at 2x106 cells/well 
in 24 well plates. 10 µg of each construct within the pools A, B, C, D, E, F, G or 
individual constructs (F-1/14/15/16/29/30/31) as well as 10 µg of AlMV-RNA3 
particles were added per ml and incubated at 37°C in 5% CO2 for 72 hours. Un-
stimulated cells were used as control. Cell cultures were washed once in PBS and 
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resuspended in cRPMI supplemented with 5 ng/ml IL-7 and 5ng/ml IL-15 (R&D 
Systems).  PBL were plated at 106 cells/well into new 24-well plates and incubated at 
37°C in 5% CO2 for 7 days.  Cells were washed and resuspended in cRPMI and plated 
at 105 cells/ well into coated ELISpot plates. Cells were restimulated with 10ug/ml of 
the pooled ag and incubated for 72 hours at 37°C in 5% CO2.  ELISpot plates were 
developed as described below  (2.5.2.5). 
2.5.2.4 T-helper recall  responses to AlMV-RSV-F-constructs 
In order to check for potential CTL-recall responses cryopreserved PBMC were 
thawed at 37°C for 5 min, washed with complete RPMI and resuspended in cRPMI 
containing 13 ng/ml GM-CSF and 15 ng/ml Il-4 (both R&D Systems, Minneapolis 
MN).  PBMC were plated at 2x106 cells/well in 24 well plates. 10 µg of each 
construct within the pools A, B, C, D, E, F, G or individual constructs (F-
1/14/15/16/29/30/31) as well as 10µg of AlMV-RNA3 particles were added per ml 
and incubated at 37°C in 5% CO2 for 72 hours. Un-stimulated cells were used as 
control. After 3 days cells were harvested, counted and brought to a final 
concentration of 1x106 cells/ml. 100 µl of the cell suspension were plated per well 
giving rise to 105 cells per well. Depending on the availability cells were plated in 
triplicates. Cells were re-stimulated with 10 µg ag per ml and analyzed in an 
ELISPOT assay (2.5.2.5) 
2.5.2.5 ELISPOT Assay 
96-well nitrocellulose-bottom plates (Multiscreen-HA, Millipore, Molsheim, France) 
were coated with 100 µl/well of anti-human IFNγ or anti-human IL-10 at a 
concentration of 15 µg/ml (1-D1K, Mabtech, Nacka, Sweden) and incubated at 4°C 
over the weekend.  The plates were washed six times with 1X PBS and blocked with 
200 µl/well of cRPMI.  Cells (2.5.2.3, 2.5.2.4) were plated in a volume of 100 µl/well 
to give 105 cells/well.  PBMC were cultured in media alone as a negative control, and 
stimulated with 10 µg/ml Concanavalin A (Con A; Sigma Chemical Co.) or 
Phytohemagglutinin (PHA) as positive control.  3 to 6 wells were plated depending on 
the availability of cells. Cell cultures were incubated for 48 hours at 37°C in 5% CO2. 
ELISPOT plates were washed six times with 1X PBS and incubated for 3 hours at RT 
with 100 µl/well of biotinylated anti-human IFNγ (Mabtech) or anti-human IL-10 
(Mabtech) at a concentration of 1 µg/ml.  Plates were washed six times with PBS and 
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incubated for 1 hour with 100 µl/well of Streptavidin-HRP (Mabtech) at RT 
ELISPOT plates were washed a final time in 1X PBS and developed for 30 minutes 
with 100 µl/well of peroxidase substrate “AEC” kit (Vector Laboratories, 
Burlingame, CA), followed by rinsing in tap water.  Plates were stored over night in 
the dark at room temperature, and spots were counted using a VersaScan microplate 
reader (Velocity 11, Palo Alto, CA).  The mean totals of IFNγ spot-forming cells 
(SFC) in triplicate wells were determined and expressed as numbers of SFC per 106 
PBMC.  
2.5.2.6 Cytokine ELISAs 
Cytokines in the supernatant of the ELISpot plates (2.5.2.5) were quantified using 
commercially available enzyme-linked immunosorbent assays (ELISAs; R&D 
Systems, Minneapolis, MN) according to manufacturer’s guidelines. All 
determinations were made in duplicate.  In some experiments, cytokines and 
chemokines were quantified using the Luminex 100 multiple cytokine detection 
assays following manufacturers instruction (R&D Systems, Minneapolis, MN).  
2.5.3 Analysis of AlMV-RSV-F-constructs in silico  
2.5.3.1 Programs 
ProPred [208] (http://www.imtech.res.in/raghava/propred/) is based on an algorithm 
developed by Hammer et al. [209, 210]. It uses a virtual matrix approach that is based 
on pocket profiles and allows 51 allele specific HLA-DR predictions. Most pockets in 
the human HLA-DR groove have distinct chemical and size characteristics. Each 
HLA-DR pocket can be characterized by "pocket profiles," a quantitative 
representation of the interaction of all natural amino acid residues with a given 
pocket. A small database of profiles is sufficient to generate a large number of HLA-
DR matrices, representing the majority of human HLA-DR peptide-binding 
specificity. AlMV-RSV-F-9/12/14/24/29/30/31 sequences were loaded into the 
program; the threshold set on 10% and a tabular presentation chosen. Predictions were 
run for: HLA-DR-0101, HLA-DR-0404, HLA-DR-1101 and HLA-DR-1501. Each 
peptide was assigned a rank, a score and the percentage of highest score compared 
with the best possible binder.   
RankPep [211] (http://www.mifoundation.org/Tools/rankpep) uses a position specific 
scoring matrix. Each matrix is the result of an alignment of at least 5 peptide 
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sequences of medium or high affinity to the specific HLA class II molecule. Every 
matrix yields an optimum sequence that gives the highest score. For each possible 
9mer, the server outputs its score and the percentage of the optimum score. 
Additionally peptides predicted by the cleavage model are highlighted. Predictions 
were run for AlMV-RSV-F-9/12/14/24/29/30/31 in combination with HLA-DR-0101, 
HLA-DR-0404, HLA-DR-1101, HLA-DR-1501, HLA-DR51 and HLA-DR53. All 
possible peptides were ranked.  
SYFPEITHI [212] (http://syfpeithi.bmi-heidelberg.com) is an algorithm based on 
motif matrices deduced from natural ligands by single ligand analysis and Edman 
pool sequencing. For MHC-class II epitope prediction the program assigns every 15-
mer a score, gives its sequence and starting position. The same score can be assigned 
to several peptides. Predictions were run for AlMV-RSV-F-9/12/14/24/29/30/31 in 
combination with HLA-DR-0101, HLA-DR-0404, HLA-DR-1101 and HLA-DR-
1501. 
2.5.3.2 Analysis and comparison of prediction results 
To compare the different peptide sets, generated by the three algorithms (2.5.3.1), 
every peptide was assigned a rank, starting at 1 towards the rank of the last possible 
peptide. To further facilitate the comparison and stress the status of high ranked 
peptides the inverted rank (inverted rank = 1 / rank of peptide) was calculated; so that 
the first peptide obtained the value 1, the second 0.5, the third 0.333 and so on. Since 
SYFPEITHI does not rank the peptides, but assigns them scores, which can be 
obtained by several peptides, either the highest, lowest or average rank of a peptide 
within its scoring group was considered, depending on the analysis.  
Two sets of peptides were analyzed: Pure RSV-peptides, which only contain amino 
acids from the RSV-F-protein, and chimeric RSV peptides, which contained vector 
derived amino acids from the N-terminus (MS) or the C-terminus (VDSSSQ).
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Figure 3-1: Alignment of the RSV-F-Protein Sequence with 34 AlMV-RSV-F-peptides.  
The diagram shows the aa sequence 1-574 of the RSV-F-protein. Functional domains of the F protein are shown above and the 34 overlapping peptides are shown below the RSV-
F aa sequence. RSV-F structure and function: Signal peptide (aa 1-21). F2 domain (aa 22-109) is connected with the F1 domain via a cysteine bridge C69-C212 (not shown). 
Heptad-repeat 3 (HR3: aa 53-100). Furin cleavage site I (aa 106-109). Cleavage peptide (aa 110-136). Furin cleavage site II (aa 132-136). Fusion peptide (aa 137-148). Heptad 
repeat 1 (HR1: aa 153/157 – 207/209). Heptad repeat 2 (HR2: aa 476/482-520). Transmembrane domain (aa 525-550). Intracellular domain (aa 551-574). AlMV-RSV-F-
peptides: The 34 overlapping peptides F1 through F34 are shown below the F-protein sequence. Each peptide is 24 aa in length, except peptide 34 (25aa), and overlaps with the 
adjacent one by 8 aa.   F1: 22-4
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Since the F protein is directed into the rER through its signal peptide (aa 1-21), where 
the latter is removed, the signal peptide was not included in the library. The first 
peptide (F-1) started, therefore, at aa 22 within the RSV F protein. All peptides, 
except F-34, were 24aa in length; F-34 was 25aa in length. Figure 3-1 gives a detailed 
view of the primary structure of RSV-F and the spanning peptides selected. 
3.1.1.2 Library Construction: the pBR-RSV-constructs 
34 PCR amplified RSV-F-peptides were cloned via KpnI and SalI into the AlMV 
RNA3-based vector pBR (2.2.1.1). The pBR-vector is a pSP65-based cloning vector 
in which the AlMV RNA3 was inserted behind a T7 promoter to allow efficient 
transcription of RNA for inoculation of plants (Figure 3-2).  
 
T7 P3 
GGTACCATGAGT-Pep-GTCGACAGTTCTTCACAA 
                  M     S   -Pep-   V     D      S      S     S      Q 
SmaI SalI KpnI 
Figure 3-2: Schematic overview of the 
pBR vector 
The pBR-vector was engineered through 
cloning of AlMV RNA 3 behind the T7 
Promotor of the pSP65 vector (T7). P3 is 
the AlMV cell to cell movement protein. 
Pep represents a foreign peptide fused to 
the AlMV-coat protein (CP). Restriction 
sites used for cloning (KpnI, SalI) or 
linerization (SalI) are indicated.  
The nucleotide sequence between KpnI (GGTACC) and SalI (GTCGAC) is shown together with the 
corresponding aa-sequence. Every peptide is flanked by MS on its N-terminal and by VDSSSQ on its C-
terminal. The creation of the SalI site led to the insertion of two additional aa (VD), which are not part 
of AlMV-CP.  
Multiple clones of each construct were created and sequenced to verify sequence 
accuracy of each cloned peptide (2.2.2). Plasmid DNAs were SmaI linearized, DNA 
purified and equivalent amounts of DNA used for in vitro transcription reactions 
(2.2.4). Transcription efficacy was analyzed on a 1% (w/v) agarose gel. Similar 
amounts of each transcript were used for inoculation of P12 plants. Three plants were 
inoculated per construct (2.3.1). Tissue samples from inoculated (i) and non-
inoculated (n) leaves and photographs of plants to document symptoms were taken at 
4, 7, 10 and 14 days post inoculation (dpi) (2.3.1). Total protein was prepared from 
the collected samples (2.3.3), separated via SDS-PAGE, electro-blotted onto PVDF-
membrane and coat protein detected by Western blotting using anti AlMV-CP 
antibodies labeled with alkaline phosphatase (2.3.4).  
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3.1.1.3 Plant symptoms and Western analysis 
Infection by pBR-RSV-F-1/2/3.../33/34 caused a variety of symptoms in the i- as well 
as in the n-leaves. Symptoms were compared to plants inoculated with in vitro 
transcripts generated from plasmid pBR (wild type AlMV) that lacks a peptide, as 
well as to a Mock control, in which transcript was replaced by distilled H2O. The 
vector itself did not cause any visible symptoms in i- and n- leaves (Figure 3-3) and 
the growth characteristics of the pBR-inoculated plants were similar to the Mock-
inoculated plants (data not shown). 
Figure 3-3: Plant infected with pBR and Western blot analysis.  
plant tissue infected with pBR (2.3.1) 
showing results from inoculated (i) and non-inoculated (n) leaves  from 3 plants (a, b, c) after 
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from: (i) no symptoms, similar to pBR 
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A) Plants infected with pBR-RSV-F constructs at 14 dpi. 
B) Western blot analysis (2.3.4.) of total protein from 
4, 7, 10 and 14 dpi. Polyclonal antibodies against AlMV CP were used to detect the virus. 
ajority of the constructs caused no visible symptoms in the i-leaf. Necro
lesions of different degrees were found when inoculating pBR-RSV-F-6/23/25/28.  
These necrotic lesions led to leaf-death after 4 dpi (pBR-RSV-F-25; Figure 3-4e) or 7 
dpi (pBR-RSV-F-6/23/28; data not shown).  
The constructs gave symptoms that varied 
(Figure 3-4a; pBR-RSV-F-2/7/8/15/16/17/18), (ii) mild symptoms, mostly yellowing 
of the veins and mosaic pattern formation (Figure 3-4b and e, pBR-RSV-F-
1/3/4/5/910/11/12/14/19/20/26/27/29/30/32/33/34, (iii) severe symptoms, vein 
yellowing, pattern formation, leaf wrinkling and stunting of the apical meristem;  
(Figure 3-4d, pBR-RSV-F-13/22/23/24/28/31). pBR-RSF-F-6 and 25, which caused 
death of the inoculated leaf failed to establish a systemic infection, although, some 
plants showed signs of systemic infection after more than 14 dpi (Figure 3-4 e). 
 
  
 
igure 3-4: Plants infected with a)  pBR-RSV-F-8; b) pBR-RSV-F-14; c) pBR-RSV-F-9; d) pBR-RSV-
-24; e) pBR-RSV-F-25 and Western blot analysis.  
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A) Plants infected with pBR-RSV-F constructs at 14 dpi.  
B) Western blot analysis (2.3.4) of total protein from plan
different pBR-RSV-F constructs (2.3.1) showing re
inoculated (n) leaves  from 3 plants (a, b, c) after 4, 7, 10 and 14 dpi. Polyclonal antibodies 
against AlMV CP were used to detect the virus. 
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Western analysis of infected tissue samples indicated that recombinant CP was found 
estern blot analysis for each construct, an optimal time 
in all inoculated leaves after 4 dpi, indicating that all the chimeras were replicated in 
the P12 plants (Figure 3-4 a-e). In 29 out of 34 constructs recombinant CP could be 
detected in n-leaves 4 to 10 dpi, indicating that systemic movement occurred but at 
various rates (Figure 3-4 b-d). For constructs pBR-RSV-F-2/6/8/16/25 none or only 
sporadic systemic movement was indicated by Western-blot analysis (Figure 3-4a, e). 
Over 50% of the chimeras (18 out of 34) stably maintained the insert after 14dpi 
(Figure 3-4 b-d) 25% (9 out of 34) converted to wt-size CP (data not shown) and 
another 20% (7 out of 34) showed variation in stability between different plants (data 
not shown). Table 3-1 gives a detailed view of local and systemic movement as well 
as stability of every construct.  
3.1.1.4 Yields and purities 
Based on the results of the W
for harvest was determined. The best harvest period was usually between 4 and 7 dpi, 
when CP-expression in i-leaves was at a peak and systemic movement had begun, and 
in most cases, recombination to wt-like construct had not yet occurred. Constructs 
pBR-6/7/17/25/32/33/34, which failed to produce stable chimeric AlMV-CP were not 
produced in this study. In general, up to 60 plants (approximately 200 to 400 g of leaf 
material) were used to generate mg quantities of recombinant virus. Plants were 
harvested and virus purified as described (2.3.2). Total protein yield was determined 
using Bradford Protein Assay (2.3.5). The relative purity of each virus preparation, 
that gave an indication of the presence of wild type like virus particles possibly as a 
result of recombination, was determined by SDS-PAGE and Coomassie staining 
followed by densitometry analysis (2.3.4). Contamination with plant proteins was in 
the range of approximately 5%. Yields and purities are shown in Table 3-1. Yields 
ranged between less than 10µg/g (pBR-RSV-F-2) and up to 280µg/g (pBR-RSV-F-
11). Interestingly the pBR-vector itself gave a yield of 50µg/g after 7dpi and 38µg 
after 14dpi. Purities between 20% (pBR-RSV-F-2) and close to 100% (pBR-RSV-F-
4/5/9/11/30) were reached (Table 3-1). Besides construct specific characteristics final 
yields and purities could further be influenced by many other factors like transcription 
efficacy, age of plants, time of harvest and purification procedures.  
  
Table 3-1: AlMV-RSV-F-constructs: peptide amino acid composition; pI; charge; movement; yields and purities 
Position aa-Composition and physico-chemical properties of RSV-F-peptide/the resulting chimeric AlMV-CP Viral Movement Purification 
# 
First 
aa 
Last 
aa 
RSV-F-sequence 
basic acidic hydro-phobic polar   pI charge Loc. Sys. Stab.
Yield
µg/g
Purity 
% 
               
wt AlMV-CP
  
             
           
          
           
           
             
           
            
           
          
              
           
              
           
            
            
             
             
          
           
            
         
           
           
          
          
0/25 0/22 0/77 0/56 0/8.6
 
0/3.8
 
+ + + 45 100
1 22 45 CFASGQNITEEFYQSTCSAVSKGY 1/26 2/24 7/84 12/68
 
 4.4/8.1 -1.1/2.8
 
+ + + 11
 
56
2 38 61 SAVSKGYLSALRTGWYTSVITIEL 2/27 1/23 10/87 9/65 8.8/8.8 0.9/4.8
 
+ +/- +/- 3 20
3 54 77 TSVITIELSNIKENKCNGTDAKVK 4/29 3/25 7/84 9/65 8.2/8.6 0.9/4.8 + + + 137
 
50
4 70 93 NGTDAKVKLIKQELDKYKNAVTEL 5/30 4/26 8/85 6/62 8.6/8.7
 
0.9/4.83 + + + 44 100
5 86 109 YKNAVTELQLLMQSTPPTNNRARR 4/29 1/23 6/83 10/66
 
11/9.2 2.9/6.8 + + + 21 95
6 120 125 PTNNRARRELPRFMNYTLNNAKKT 6/31 1/23 5/82 9/65 11.7/9.4 4.9/8.8 + +/- +/- np np
7 118 141 TLNNAKKTNVTLSKKRKRRFLGFL 8/33 0/22 8/85 7/63 12.4/9.6 7.9/11.8
 
+ + - np
 
np
 8 134 157 KRRFLGFLLGVGSAIASGVAVSKV 4/29 0/22 13/90 3/59 12.1/9.3 3.9/7.8
 
+ - + f f
9 150 173 SGVAVSKVLHLEGEVNKIKSALLS 3/28 2/24 11/88 5/61 8.7/8.8 1.1/5 + + + 86 100
10 166 189 KIKSALLSTNKAVVSLSNGVSVLT 3/28 0/22 11/88
 
 9/65 10.3/9.1 2.9/6.8 + + + 24 83
11 182 205 SNGVSVLTSKVLDLKNYIDKQLLP 3/28 2/24 9/86 8/64 8.7/8.8 0.9/4.8 + + +/- 280 95
12 198 221 YIDKQLLPIVNKQSCSISNIETVI 2/27 2/24 9/86 10/66
 
 6.2/8.4 -0.1/3.8 + + + 43
 
80
13 214 237 ISNIETVIEFQQKNNRLLEITREF 3/28 4/26 9/86 8/64 4.9/8.3 -1.1/2.8 + + +/- 5 40
14 230 253 LLEITREFSVNAGVTTPVSTYMLT 2/27 2/24 9/86 8/64 6.4/8.6 -0.1/3.8 + + + 20 80
15 246 269 PVSTYMLTNSELLSLINDMPITND 0/25 3/25 7/84 10/66 3.2/7.4 -3.1/0.8 + + - 135 90
16 262 285 NDMPITNDQKKLMSNNVQIVRQQS 3/28 2/24 5/82 11/67
 
 8.8/8.8 0.9/4.8 + - - 194 25
17 278 301 VQIVRQQSYSIMSIIKEEVLAYVV 2/27 2/24 11/88 8/64 6.4/8.5 -0.1/3.8
 
+ + - np
 
np
 18 294 317 EEVLAYVVQLPLYGVIDTPCWKLH 1/26 3/25 11/88 5/61 4.6/7.8
  
-2/2 + + + f f
19 310 333 DTPCWKLHTSPLCTTNTKEGSNIC 2/27 2/24 4/81 12/68 7/8.2 0/3.9 + + + 109
 
71
20 326 349 TKEGSNICLTRTDRGWYCDNAGSV 3/28 3/25 5/82 10/66 6.2/8.3 -0.2/3.8 + + +/- 58 75 
21 342 365 YCDNAGSVSFFPQAETCKVQSNRV 2/27 2/24 7/84 11/67 6.2/8.3 -0.2/3.8 + + + 85 75
22 358 381 CKVQSNRVFCDTMNSLTLPSEINL 2/27 2/24 7/84 11/67
 
 6.2/8.3 -0.2/3.8 + + + 26 80
23 374 397 TLPSEINLCNVDIFNPKYDCKIMT 2/27 3/25 7/84 9/65 4.4/8.1 -1.2/2.8
 
+ + - 14 56
24 390 413 KYDCKIMTSKTDVSSSVITSLGAI 3/28 2/24 7/84 10/66 8.2/8.6 0.9/4.8 + + + 29 75
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Position aa-Composition and physio-chemical properties of RSV-F-peptide/the chimeric AlMV-CP Viral Movement Purification 
 
 
# 
First 
aa 
Last 
aa 
RSV-F-sequence 
basic acidic hydro-phobic polar   pI charge Loc. Sys. Stab.
Yield
µg/g
Purity 
% 
               
25 406 429           
          
            
          
               
            
            
           
           
          
           
VITSLGAIVSCYGKTKCTASNKNR 4/29 0/22 7/84 11/67 9.6/9 3.8/7.8 + +/-
 
- np np 
26 422 445 CTASNKNRGIIKTFSNGCDYVSNK 4/29 1/23 5/82 12/68 9.1/8.9 
 
2.9/6.8 + + +/- 53 90 
27 438 461 GCDYVSNKGMDTVSVGNTLYYVNK 2/27 2/24 6/83 11/67
 
6/8.4 -0.1/3.8
 
+ + + 15 80
28 454 477 NTLYYVNKQEGKSLYVKGEPIINF 3/28 2/24 7/84 9/65 8.6/8.7 0.9/4.8 + + + 10 43
29 470 493 KGEPIINFYDPLVFPSDEFDASIS 1/26 5/27 9/86 5/61 3.5/6.9 -4.1/-0.2
 
+ + +/- 91 70
30 486 509 DEFDASISQVNEKINQSLAFIRKS 3/28 4/26 9/86 8/64 4.7/8.3 -1.1/2.8
 
+ + + 142 95
31 502 525 SLAFIRKSDELLHNVNAGKSTTNI 3/28 2/24 9/86 8/64 8.8/8.8
 
1.2/5 + + + 144 80
32 518 541 AGKSTTNIMITTIIIVIIVILLSL 1/26 0/22 14/91 7/63 9/8.8 0.9/4.8 + + - np np
33 534 557 IIVIIVILLSLIAVGLLLYCKARS 2/27 0/22 15/92 5/61 9.2/8.9 1.9/5.8 + + - np np
34 550 574 CKARSTPVTLSKDQLSGINNIAFSN
 
3/28 1/23 8/85 11/67
 
 9.2/8.9
 
1.9/5.8
 
+ + - np np
 
The Table shows the biological (movement, stability, yield, purity) and physico-chemical characteristics of the 34 pBR-RSV-F constructs in comparison to AlMV-CP 
without any displayed peptide. #: AlMV-RSF-construct number or CP. Number in regular font (9, 10, 11, 12, 14, 15, 16, 19, 20, 21, 22, 26, 27, 29, 30, 31) indicate good, 
those in italic (1, 3, 4, 5, 24, 28) difficult and those in bold (2, 6, 7, 8, 13, 17, 18, 23, 25, 32, 33, 34) unexpressible constructs. Position: The first and last aa position within 
the RSV-F protein are shown.  Sequence: RSV-F-peptide sequence from first to last aa; aa-composition: Number of basic (K, R), acidic (D, E), hydrophobic (A,I,L,F,W,V) 
and polar (N,C,Q,S,T,Y) amino acids of the RSV-F-peptide and the resulting AlMV-RSV-F construct. Physico-chemical characteristics: From the aa composition resulting 
isoelectric point (pI) and charge at pH7 of the RSV-F-peptide and the resulting chimeric AlMV-CP molecule are shown. Viral Movement: Analysis of local (Loc.) and 
systemic (Sys) movement of the pBR-RSV-F constructs by symptom formation and Western blot analysis. The stability (Stab.) of the construct was determined by the 
presence of wt-size CP in the upper leaves of the infected plant. Purification: Yields are given in µg/g plant material, the purity in % indicates the presence of  wt-size CP in 
the virus preparation produced probably as a result of recombination. Contamination with other plant proteins is included and contributed with  around 5% to the total purity. 
Variations between different constructs and batches could be observed. Constructs pBR-RSV-F-6/7/17/25/32/33/34 unlikely to give reasonable yields were not produced 
(np). Purification of constructs  pBR-RSV-F-8/18 failed (f). 
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The production of constructs pBR-RSV-F-8 and 18 failed due to loss of chimeric 
particles during purification. Chimeric CP could be detected by Western Blot analysis 
of total protein in the i-leaf (Figure 3-4a) as well as in samples from initially ground-
up plant material in preparation for virus purification (Figure 3-5 a and b, lane G). 
The following centrifugation steps, however, resulted in the chimeric particles 
sticking to the pellet of the “green” membrane fraction (Figure 3-5 a and b, lanes P 
PEG, P 30k, P TB). The end result of the purification process was an almost complete 
loss of particles (Figure 3-5 a and b, lane F).  
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Figure 3-5: Purification of a) pBR-RSV-F-8 and b) pBR-RSV-F-18 
The Coomassie-stained PAGE gel (2.3.4.) shows different steps in the purification process. M: 
molecular size marker; wt: wild type AlMV-CP; F: final virus preparation; P-TB: Pellet table top 
centrifugation; S 30k: supernatant after centrifugation at 30.000g; P30k pelletafter centrifugation at 
30.000 g; S PEG: supernatant after PEG precipitation and centrifugation at 8000g; P PEG: pellet 
after PEG precipitation and centrifugation at 8000g; S 8000: supernatant after centrifugation at 
8000g; G: initially ground plant material. 
 
Constructs pBR-RSV-F-4/5/10/12/22/24/27 had to be produced several times in order 
to obtain sufficient quantities for further experiments. These “repetition experiments” 
allowed an estimation of variability in yield and purity between different batches of 
the same construct. Construct yields varied by up to 50% and purity up to 20%.  
To obtain concentrations of at least 0.2mg/ml for dendritic cell (DC) studies for 
identification of CD4+ T-cell epitopes (2.5.2) and 2mg/ml for mice immunization 
(2.5.1), yields of more than 25µg/g and purities of at least 75% were sufficient. This 
led to the successful expression of 22 out of 34 constructs for DC assays (65%; pBR-
RSV-F-1/3-5/9-12/14-16/19-22/24/26-31) and 16 out of 34 (47%; pBR-RSV-F-9-
12/14-16/19-22/26/27/29-31) for mice studies.  
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3.1.1.5 Peptide analysis 
Fusion of foreign peptides to the N- terminus of AlMV-CP could influence symptom 
formation, movement, stability and yield of the chimeric AlMV particles.  The effect 
could be due to (i) physico-chemical properties, such as length, size, molecular weight 
(MW), hydrophobicity, polarity, charge and isoelectric point (pI) of the peptide or (ii) 
its biological activity, which could arise from specific sequence motifs.  
To determine the polarity, hydrophobicity, charge and pI the number of strongly basic 
(K, R), acidic (D, E), hydrophobic (A, I, L, F, W, V) and polar (N, C, S, Q, T, Y) aas 
were identified and pI and charge calculated (2.2.3). Additionally the pI and charge of 
the resulting chimeric AlMV-CP protein was calculated (Table 3-1).  
In an attempt to statistically compare peptide properties of well and poorly expressed 
peptides the constructs were divided into two groups based on their performance. 
Constructs pBR-RSV-F-9-12/14-16/19-22/26/27/29-31 were part of the well-
expressed group whereas constructs pBR-RSV-F-2/6-8/13/17/18/23/25/32-34 were 
considered poorly or non expressible. Constructs pBR-RSV-F-1/3/4/5/24/27/28 were 
not considered, since they showed no clear tendency. For each group the average 
content of hydrophobic, polar, basic and acidic aas was calculated as well as the 
average pI and charge value (Figure 3-6). Two subgroups of poorly expressed 
peptides were identified. Constructs pBR-RSV-F-2/17/18/32 had significant higher 
amounts of hydrophobic aas. Constructs pBR-RSV-F-6/7/25/34 contained more basic 
aas than acidic aas and the resultant chimeric CPs were positively charged (Figure 
3-6). Constructs pBR-RSV-F-8 and 33 were both: highly positively charged and 
hydrophobic. Only, constructs pBR-RSV-F-13 and 23 had an aa-composition similar 
to the expressible peptides.  
To determine whether peptides could be expressed due to their aa composition or due 
to the presence of specific biological activity, peptides were aligned with the RSV-F 
sequence (Figure 3-1). Constructs pBR-RSV-F-5 (aa 86-109) and pBR-RSV-F-6 (aa 
102-125) contain the furin cleavage site I (RARR, aa 106-109); pBR-RSV-F-7  (aa 
118-141) and pBR-RSV-F-8 (aa 134-157) covered the entire or partial furin cleavage 
site II (KRKRR, aa 132-136) and the fusion peptide (FLGFLLGVGSAIA, aa 137-
148); pBR-RSV-F-32 (aa 518-541) and pBR-RSV-F-33 (aa 524-557) covered part of 
the trans-membrane domain (IMITTIIIVIIVILLSLIAVGLLLYC, aa 525-550). 
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Figure 3-6: Comparison of amino acid content of expressible and unexpressible peptides and the 
corresponding chimeric CP.  
The shown values result from averaging the number of hydrophobic (A,I,L,F,W,V) and polar 
(N,T,Q,S,T,Y) amino acids (A) as well as the charge of the corresponding chimeric AlMV-CP (B).  The 
well expressed peptides/constructs pBR-RSV-F-9-12/14-16/19-22/26/29-31 or the unexpressible 
peptides pBR-RSV-F-6/7/25/34 (charged) and pBR-RSV-F-2/17/18/32 (neutral) were analysed.          
A) Content of hydrophobic and polar amino acids in expressible or unexpressible 24mer peptide        
B) Charge of chimeric AlMV-CP displaying expressible or unexpressible 24mer peptides. The charge 
of wt AlMV-CP  is 3.8. 
Besides being either very basic (Furin cleavage site I and II) or very hydrophobic 
(fusion protein, trans-membrane domain) these peptides also have a specific 
biological function, such as furin cleavage, fusion or membrane anchoring, which 
could affect peptide expression. However, constructs pBR-RSV-F-
2/13/17/18/23/25/34 did not have any known biological activity, but still could not be 
expressed in the AlMV system. It is possible that the amino acid sequence was the 
limiting factor. 
3.1.1.6 Improvement of chimeric CP expression and particle production 
3.1.1.6.1 Shifting the sequence: the pBR-RSV-F-bis constructs 
In order to manipulate the aa-composition of un- or difficult-to-express peptides so 
that the total charge, pI and hydrophobicity were closer to those peptides that were 
more easily expressed their sequence was shifted until an optimum was reached. If 
shifting alone did not result in improved aa-composition the sequence was 
additionally shortened or lengthened. In most cases the 8 core aas, those that did not 
overlap with the adjacent one were kept as well as 4 adjacent aas. This ensured that 
the whole RSV-F sequence was still covered and an overlap of 4 aa between the 
different constructs was maintained. The new constructs, pBR-RSV-F-6bis, 12bis, 
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17bis, 18bis and 24bis, were designed, cloned and expressed (2.2.1.2; 2.3). Constructs 
pBR-RSV-F-7 and 8 could not be improved because an optimal or better aa 
composition could not be reached within this part of the RSV F sequence. All bis-
constructs, except 24bis, had improved performance with less severe symptoms, 
better movement and stability. However, yields and purities were still poor and 
therefore they could not be purified to levels sufficient for immunological studies 
(data not shown).  
3.1.1.6.2 Adding enhancing aas: the pBR-RSV-F-DE and SSQ constructs 
The pBR-RSV-F-bis constructs demonstrated that it was possible to improve peptide 
expression to some extent. However, this approach is limited by the actual amino acid 
sequence itself and could therefore not be applicable in many strategies. Adding aas to 
either the N- or C- terminus or both peptide termini could be an alternate and general 
applicable strategy to compensate for high content of basic or hydrophobic aas.  
The highly necrotic construct pBR-RSV-F-25 (charge: +4; Figure 3-4 e) and its 
corresponding bis-construct 24bis (charge +2; Figure 3-7 a), that both caused leaf 
death 4dpi and failed to establish a persistent systemic and stable infection, were 
chosen to demonstrate this approach.  After adding the strongly acidic aspartic acid 
(D) and glutamic acid (E) the net charge of the peptide was zero (pBR-RSV-DE-24bis 
and 24bis-DE) or –2 (pBR-RSV-DE-24bis-DE). DE was added either to the N- or C-
terminus to investigate positional effects. A detailed analysis of the constructs is 
shown in Table 3-2a. 
Table 3-2: pBR-RSV-F-DE (a) and 25bis (b) -constructs 
 RSV-F-derived peptide Peptide/construct Biol.Activity  
 pBR-RSV-F 
construct First 
aa 
Last 
aa Sequence 
KR/DE 
ratio charge loc. sys. stab. 
a) 25 406 429              VITSLGAIVSCYGKTKCTASNKNR 4/0  3.8/7.8 + +/- - 
 24bis 403 426       SSSVITSLGAIVSCYGKTKCTASN 2/0  1.9/5.8 + - - 
 DE24bis 403 426 DESSSVITSLGAIVSCYGKTKCTASN 2/2 -0.2/3.8 + + +/- 
 24bisDE 403 426      SSSVITSLGAIVSCYGKTKCTASNDE 2/2 -0.2/3.8 + - - 
 DE24BISDE 403 426 DESSSVITSLGAIVSCYGKTKCTASNDE 2/4 -2.2/1.8 + + + 
b) 25bis KTK 414 426                                VSCYGKTKCTASN 2/0 1.9/5.8 + + + 
 25bis LTL 414 426                                VSCYGLTLCTASN 0/0 -0.2/3.8 + + + 
 25bis ETE 414 426                                VSCYGETECTASN 0/2 -2.2/1.8 wt wt wt 
The Table shows the biological and physico-chemical characteristics of the pBR-RSV-F-DE (a) and 
25bis (b) constructs. The letters in bold show the aa added or changed. The KR/DE ratio determines the 
number of highly basic vs. acidic aas. As biological activities local (loc.) and systemic (sys) movement 
as well as theinsert stability (stab) are analyzed.  
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Figure 3-7: Plants infected with a) pBR-RSV-F-24bis; b) pBR-RSV-F-DE-24bis; c) pBR-RSV-F-DE-
24bis-DE  and Western blot analysis.  
A) Plants infected with pBR-RSV-F constructs at 14 dpi. 
B) Western blot analysis (2.3.4.) of total protein from plant tissue infected with constructs from 5 
different pBR-RSV-F constructs (2.3.1) showing results from inoculated (i) and non-
inoculated (n) leaves  from 3 plants (a, b, c) after 4, 7, 10 and 14 dpi. Polyclonal antibodies 
against AlMVCP were used to detect the virus. 
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Figure 3-8: Leaves inoculated with a) pBR-RSV-F-24bis; b) pBR-RSV-F-DE-24 bis; c) pBR-RSV-F-
DE-24bis-DE 
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Both constructs pBR-RSV-F-DE-24bis and pBR-RSV-F-DE-24bis-DE infected plants 
locally and systemically and remained stable at least until 10 dpi (Figure 3-7 b and c). 
Interestingly construct pBR-RSV-F-24bis-DE showed no improvement (data not 
shown). pBR-RSV-DE-24bis-infected plants gave mild symptoms, including vein 
yellowing and stunting (Figure 3-7 b). pBR-RSV-DE-24bis-DE instead caused severe 
systemic necrosis, which led to plant death after 14dpi (Figure 3-7 c). 
Analysis of inoculated leaves after 9 dpi revealed large necrotic spots and spreading 
necrosis for pBR-RSV-F-24bis, large necrotic spots and starting spreading for pBR-
RSV-DE-24bis-DE but small and contained necrotic lesions for pBR-RSV-DE-24bis 
(Figure 3-8). Purification of virus from plants infected with the three constructs 
indicated low yields for pBR-RSV-F-24bis and DE-24bis-DE (1µg/g) but almost 10 
times higher yields for pBR-RSV-F-DE-24bis (8 µg/g; purity 75%). 
 
For peptides that had a high content of hydrophobic amino acids, polar amino acids 
serine (S) and glutamine (Q) were added to the N-terminus of the peptide to determine 
if the hydrophobicity could be balanced by polar amino acids to improve levels of 
expression. The SSQ-motif was chosen since wt AlMV-CP starts with MSSSQ. 
Peptide insertion via the restriction enzymes KpnI/SalI causes the N-terminus of the 
peptide to be flanked by amino acids methionin and serine (MS) and the C-terminus 
with serine-serine-glutamine (SSQ) (Figure 3-2). 
By the addition of SSQ to the N-terminus any inserted peptide is thus flanked with 7 
polar amino acids. Construct pBR-RSV-F18 contained 5 polar and 11 hydrophobic 
amino acids and the corresponding bis construct 12 polar vs. 9 hydrophobic aas. The 
resulting SSQ constructs contained consequently 8 (18SSQ) and 15 (18bisSSQ) polar 
aas. A detailed analysis of SSQ constructs is shown in (Table 3-3). 
Table 3-3: AlMV-RSV-F-SSQ constructs 
RSV-F-derived peptide Peptide properties AlMV-RSV-F 
construct First  
aa 
Last 
aa Sequence 
polar/ 
hydro. charge 
18 294 317        EEVLAYVVQLPLYGVIDTPCWKLH 5/11 -2 
18SSQ 294 317 SSQEEVLAYVVQLPLYGVIDTPCWKLH 8/11 -2 
18bis 299 326                      YVVQLPLYGVIDTPCWKLHTSPLCTTNT 12/9 0 
18bisSSQ 299 326               SSQYVVQLPLYGVIDTPCWKLHTSPLCTTNT 15/9 0 
The Table shows physico-chemical characteristics of the pBR-RSV-F-SSQ constructs. The letters in 
bold show the aa added. The polar-hydro. ratio determines the number of polar vs. hydrophobic aas.  
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P12 plants infected with pBR-RSV-18 and 18bis showed no symptoms, like wt 
AlMV, whereas after infection with pBR-RSV-18SSQ and 18bis-SSQ mild symptoms 
could be observed (Figure 3-9). All constructs moved locally and systemically but the 
SSQ-constructs were less stable.  
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Figure 3-9: Plants infected with a)  pBR-RSV-F-18, b) pBR-RSV-F-SSQ-18bis and Western blot 
analysis.  
A) Plants infected with pBR-RSV-F constructs at 14 dpi. 
B) Western blot analysis (2.3.4.) of total protein from plant tissue infected with constructs from 5 
different pBR-RSV-F constructs (2.3.1.) showing results from inoculated (i) and non-
inoculated (n) leaves  from 3 plants (a, b, c) after 4, 7, 10 and 14 dpi. Polyclonal antibodies 
against AlMVCP were used to detect the virus. 
However virus could be purified from pBR-RSV-F-18SSQ, pBR-RSV-F-18bis and 
pBR-RSV-F-18bisSSQ infected plants, which was hardly possible for pBR-RSV-F-18 
(Figure 3-10).  Yields of 4, 4 and 9µg/g for pBR-RSV-F-18SSQ, 18bis and 18bisSSQ 
and purities of 50, 50 and 80%, respectively, were reached. 
18 18bis 18bis SSQ 18SSQCP-wt 
Figure 3-10: Yields and purities of 
AlMV-RSV-F-18, 18bis, 18bis SSQ 
and 18SSQ in comparison with 
AlMV-CP wt. Double bands 
indicate recombination.  
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3.1.1.6.3 Impact of size: the pBR-RSV-F-25bis, T118 and HR2 constructs 
All peptides in the study were ~24aa in length. To determine if size had an impact on 
the expression level of difficult peptides, construct pBR-RSV-F-25bis KTK (aa 414-
426) was designed. This construct has the same charge as pBR-RSV-F-24bis (+2) but 
is 11aa shorter (13aa vs. 24aa). Furthermore, in pBR-RSV-F-25bis LTL, the KTK 
motif has been mutated to LTL to give a neutral charge, and in pBR-RSV-F-25bis to 
ETE to give a negative charge of -2. Table 3-2b gives a detailed comparison of the 
constructs.  
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Figure 3-11: Plants infected with a) pBR-RSV-F-25bis, b) pBR-RSV-F-25bis ETE and Western blot 
analysis.  
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A) Plants infected with pBR-RSV-F constructs at 14 dpi. 
B) Western blot analysis (2.3.4.) of total protein from plant tissue infected with constructs from 5 
different pBR-RSV-F constructs (2.3.1.) showing results from inoculated (i) and non-
inoculated (n) leaves  from 3 plants (a, b, c) after 4, 7, 10 and 14 dpi. Polyclonal antibodies 
against AlMV CP were used to detect the virus. 
Construct pBR-RSV-F-25bis KTK gave mild symptoms with local necrotic spots in 
the infected leaf and systemic and stable movement through the whole plant similar to 
pBR-RSV-F-DE-24bis. Construct pBR-RSV-F-25bis-ETE instead showed wt-like 
symptoms with no necrosis in the infected leaf and stable, systemic movement 
through the whole plant, demonstrating once again, that negatively charged peptides 
are well tolerated and perform like wt-CP.  
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To determine whether larger peptides could be expressed in AlMV, two peptides from 
the C-terminal heptad repeat (HR2, aa 476-520) region were selected. Constructs 
pBR-RSV-F-T118, 35 aa in length, covering aas 488-522 of RSV-F, and pBR-RSV-
F-HR2, 50 aa in length, covering aas 474-523 were generated (2.2.1.2). Both 
constructs could be expressed (2.3.1) and purified (2.3.2) and yields of 26µg/g (purity 
50%) for pBR-RSV-F-T118 and 12µg/g (purity 75%) for pBR-RSV-F-HR2 were 
obtained (data not shown). Construct pBR-RSV-F-T118, displaying a fusion inhibitor, 
and pBR-RSV-F-HR2 as control, were supposed to be tested in an cell fusion assay 
[79] which so far could not be performed.  
3.1.2 Discussion 
3.1.2.1 Expression and analysis of pBR-RSV-F-constructs 
To use AlMV virus particles as a tool to screen F protein peptides for vaccine 
development 34 PCR amplified RSV-F-peptides were successfully cloned into the 
AlMV RNA3-based expression vector pBR; sequences verified, plasmid linearized, 
DNA transcribed and inoculated on P12 tobacco plants. Virus spread was monitored 
to determine the feasibility of chimeric CP expression from upper leaves and define 
an optimal time of harvest. In general, best yields and purities were obtained after 4 to 
7 dpi. For pBR-RSV-F-constructs that were easily expressed and produced, purified 
virus particles could be obtained within three days.  
Initially, 65% of the constructs could be produced with half of them to a level of 
several mgs per kg leaf tissue. The remaining 35% could not be produced under the 
standard conditions used. It is expected that since some of these peptides covered 
biological active sites, including the furin cleavage site (pBR-RSV-F-6/7), the fusion 
protein (pBR-RSV-F-7/8) or the trans-membrane domain (pBR-RSV-F-32/33), their 
production using any system would be challenging. 20% of the peptides could not be 
expressed in our system without further manipulation. Insufficient expression of 
peptides could be due to: low levels of expression or instability of virion particles. 
AlMV CP is involved in multiple steps of the viral replication cycle [38] including 
genome activation [51, 52], RNA replication [53, 54], virus assembly [55, 56], 
stability of viral RNA [57] (1.1.1), long distance movement of viral RNA [58] and 
symptom formation [59]. All of these functions could be abrogated through deletion 
of specific CP regions or even single aas [52]. However, an in depth analysis of the 
effect of CP function due to N-terminal fusion of peptides has not yet been described, 
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and it is reasonable that this could have an impact. Peptides that were difficult to 
express were classified into two groups (Figure 3-6): (i) positively charged peptides, 
in which more basic then acidic peptides were found and (ii) hydrophobic peptides in 
which hydrophobic aas dominated over polar ones. The first group of constructs 
caused more severe symptoms like local or systemic necrosis, were often disabled in 
movement and unstable (pBR-RSV-F-6/7/8/25), whereas the second group (pBR-
RSV-F-17/18/32/33) showed no or mild symptoms, moved systemically and were 
more stable, maintaining the fused peptide for longer periods of time (Table 3-1). 
In P12 plants CP is not required for genome activation [43, 49], which excludes an 
impact of the chimeric CP on this function. Since recombinant CP could be detected 
in all inoculated leaves, the expression of chimeric CP within the plant cell appeared 
unaffected, indicating functional RNA replication and stability. N-terminal peptide 
fusion most probably affected viral assembly, long distance movement and symptom 
formation.  
In additional to viral AlMV-CP function, the fusion peptide could also alter virus 
plant interactions, especially those involved in viral defense and resistance. This 
interaction results in the development of visible symptoms ranging from mild 
chlorosis to severe local or systemic necrosis. The formation of local necrotic lesions 
is known as the hypersensitive response (HR), in which a cascade of biochemical 
events result in localized cell death that prevents spread of virus and disease.  
Bendahmane et al. (1999) demonstrated that highly positively charged peptides on the 
surface of TMV virus particles affected expression levels, local and systemic 
movement, and caused a HR in tobacco [34]. Positively charged peptides presented as 
CPMV-CP fusions gave no or very low yields and sometimes even failed to induce a 
viral infection at all, but did not cause enhanced symptom formation, HR, local or 
systemic necrosis [214]. In this study, the addition of highly positively charged 
peptides as N-terminal fusion with AlMV-CP caused an HR and sometimes even 
systemic necrosis. Earlier studies by Neeleman et al. (1991) demonstrated that a 
single aa-mutation from Gln to Arg at position 29 in CP changed the corresponding 
phenotype from very mild chlorosis to necrosis. [59]. Culver et al. (1994) could 
correlate the elicitation of an HR with aa-substitutions in a TMV-CP that affected CP-
CP interactions and consequently the establishment of correct quaternary structure, 
whereas mutations in other CP positions or the disruption of the tertiary structure did 
not result in an HR [215, 216]. They further postulated that disassembly of CP 
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aggregates exposes a host “receptor” binding site. Since the N-terminal end of AlMV 
CP is directly involved in dimer formation [46, 60] it is possible that dimer formation 
and, as a result, viral assembly could be affected. Electron micrographs of HR-
eliciting or non HR-eliciting AlMV-particles could elucidate this, if they can be 
purified.  If virus particles cannot be isolated, EM from infected plant sap could give 
indications about assembly of virus particles. Furthermore the onset of genes involved 
in plant viral defense could be monitored. Bendahmane et al. (1999) found 
accumulation of PR2 mRNA in plant leaves inoculated with TMV particles that had a 
positively charged peptide fused to CP and elicited an HR [34]. PR2 is a pathogen 
related gene (PR gene) that is known to be induced by virus infection or in other stress 
situations [217]. Similar studies could be undertaken with AlMV particles.  
 
Why highly hydrophobic peptides were difficult to express in our system is less clear. 
Porta et al. (1994) found an unusual affinity of CPMV particles, which presented an 
epitope from Foot and mouth disease virus (FMDV), with cellular membranes [12]. 
The epitope (FMDV aa141-159: VPNLRGDLQVLAQKVARTL) was both positively 
charged (+2) and hydrophobic (9 hydrophobic vs. 4 polar aas) and contained a 
sequence motif (RGD), which is known to promote cell attachment in a number of 
proteins and believed to be the cell attachment site of FMDV [12, 218]. They 
postulated that the corresponding chimeric CPMV particles could be immobilized in 
the vascular tissue, thereby preventing long-distance movement and the development 
of systemic symptoms. This would also explain the difficult purification of particles, 
which were found in insoluble membrane fractions. Data generated from constructs 
pBR-RSV-F-8 and 18 strongly support this theory. First, pBR-RSV-F-8 (13 
hydrophobic vs. 3 polar aas) was unable to move systemically; second, it failed to 
induce an HR and local and systemic necrosis, even if it was highly positively 
charged (+4) (Table 3-1); third the attempt to purify pBR-RSV-F-8 particles only 
from inoculated leaves failed, since the chimeric CP remained within the “green” 
membrane fractions (Figure 3-5). Immobilization of either chimeric particles or 
individual CPs within plant cell membranes would hinder systemic movement and 
hide the postulated recognition site, blocking an HR response. Whether local 
movement was decreased or even prevented could not be determined, however, 
detection of a strong signal for CP in plant samples from inoculated tissue indicates 
possible local cell-to-cell movement. Chimeric particles from pBR-RSV-F-18 (11 
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hydrophobic vs. 5 polar aas) that moved systemically and did not elicit an HR (Figure 
3-9) were also lost in the membrane fraction during virus purification (Figure 3-5). 
The difference between the two constructs could be the higher content of hydrophobic 
aas in pBR-RSV-F-8, but more probably the presence of the complete RSV-F fusion 
peptide, which is known to integrate within cell membranes [73, 83]. Interestingly, 
constructs pBR-RSV-F-32 and 33, which partly expressed the F proteins trans-
membrane domain, were unstable and moved systemic only after converting to virus 
that had wt-size CP subunits (data not shown).  
3.1.2.2 Improvement of chimeric CP expression and particle production 
Comparison of expressible and unexpressible peptides led to the identification that 
high positive charge and high content of hydrophobic amino acids decreased or even 
prevented chimeric CP production and assembly. Physico-chemical properties of 
expressible peptides could be defined as: (i) neutral or negative charge, which resulted 
in a chimeric CP with a charge similar or below wt (3.8); (ii) a surplus of polar vs. 
hydrophobic aas (Figure 3-6). Definition of this optimal aa composition allowed 
furthermore the improvement of expressibility. Two different approaches were 
undertaken: (i) shifting, decreasing or increasing the sequence until an optimal aa 
composition was reached (pBR-RSV-F-bis constructs, 3.1.1.6.1) or (ii) adding aas in 
order to compensate for very basic or hydrophobic aas (pBR-RSV-F-DE and SSQ 
constructs, 3.1.1.6.2).  
Although the approach to improve expression through shifting, decreasing or 
increasing the sequence did result in some improvements (3.1.1.6.1) it might not be 
generally applicable. However, this strategy could be useful for the design of a 
defined peptide library that has some flexibility in length and extent of overlap 
between the peptides. 
Using the AlMV system, under optimal conditions, peptides up to a length of 50aas 
could be expressed and fair yields and purities obtained (3.1.1.6.3). However, when 
difficult or even unexpressible peptides were studied smaller peptides performed 
better. i.e. constructs pBR-RSV-F-24bis (24aas) and pBR-RSV-F25bis KTK (13aas) 
were both positively charged (+2) but showed different phenotypes in plants 
(3.1.1.6.3). Construct pBR-RSV-F-24bis induced an HR, whereas pBR-RSV-F25bis-
KTK moved systemically (Table 3-2). But decreasing the peptide size to optimize 
expression might not always be an option when designing vaccine candidates.  
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An attempt to develop an algorithm that could design an optimal peptide library using 
the above findings is being undertaken.  
 
On the other hand, adding compensating acidic amino acids DE or polar amino acids 
SSQ to compensate for basic or hydrophobic amino acids appeared to be the more 
successful approach to enhance expression of difficult peptides (3.1.1.6.2).  
Construct pBR-RSV-F-24bis was successfully enhanced through addition of aas DE. 
Necrosis of inoculated leaves was delayed and significantly reduced (Figure 3-8) and 
the virus also moved systemically (Figure 3-7). The construct pBR-RSV-DE-24bis 
gave mild symptoms, and particles could be purified, although yields were still low. 
Interestingly P12 plants inoculated with the construct pBR-RSV-F-DE-24bis-DE 
demonstrated systemic necrosis followed by death 14 dpi. This result indicated that 
even though viral movement could be improved the HR was still induced.  
Improvement of peptides with high content of hydrophobic amino acids through the 
N-terminal addition of SSQ had less striking results (3.1.1.6.2). The constructs caused 
mild visible symptoms and showed a higher recombination frequency after 10dpi. 
This might be explained with the two flanking SSSQ motifs at both ends of the 
peptide that could increase recombination (Figure 3-2, 3-9 and Table 3-3). However 
viral particles could be purified from pBR-RSV-F-18-SSQ, 18bis and 18bis-SSQ, 
which could not be achieved with the original construct pBR-RSV-F-18 (Figure 3-10) 
Adequate amounts (9µg/g) and purity (80%) for pBR-RSV-F-18bis SSQ was reached 
that allowed for its production.  
 
The results show that peptide expression through addition of compensatory amino 
acids could improve expression of peptides that could otherwise be difficult to 
produce in plants. The approach has paved the way to increase the number of peptides 
that could be expressed on AlMV particles for the display of immunogenic peptides; a 
more efficient screening of proteins could be accomplished. 
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3.2 Development of a HNK20 mimic  
Neutralization of free virus through n-abs is the most desirable B-cell response as a 
consequence of vaccination. Unfortunately, out of the many abs generated upon 
antigen exposure, only few confer neutralization. Generating antigen from n-abs 
would allow, upon immunization, the elicitation of a desired, protecting B-cell 
response (1.3.1). HNK20 is a murine anti-RSV IgA neutralizing antibody that is 
known to prevent disease [114]. Here the development of a HNK20 mimic and its use 
as AlMV presented peptide vaccine is described.  
3.2.1 Results 
Anti-RSV monoclonal ab HNK20 binding peptides were selected by phage display 
technology using two peptide libraries; (i) a random linear dodecapeptide (Ph.D.12; 
NEB) and (ii) a disulfide- constrained heptapeptide (Ph.D.-C7C; NEB) library. A pair 
of cysteine residues that is oxidized during phage secretion, so that the displayed 
peptides are presented as loops, flanks the randomized segment of the Ph.D.-C7C 
library. Both libraries have complexities of over 2 billion different clones. The 
randomized peptide sequences in both libraries are expressed as N-terminal fusion 
with the M13 minor coat protein pIII at a valency of 5 copies of the displayed peptide 
per phage particle. In the Ph.D.-12 library the first residue of the peptide-pIII fusion is 
the first randomized position, while the first randomized position in the Ph.D.-C7C 
library is preceded by alanine and cysteine. All of the libraries contain a short glycine-
glycine-glycine-serine linker sequence, which is preceded by a cysteine in the Ph.D.-
C7C library.  
Phages of both libraries were subjected to four rounds of bio panning against HNK20 
(2.4.1). Enrichment of binding phages in the eluate was verified by phage titering 
after each round of bio panning (data not shown) (2.4.2). Forty individual clones from 
the third amplification and fourth elution were tested for HNK20-binding activity by 
phage ELISA (2.4.5.1). After the third amplification, 42% from Ph.D.-C7C and 95% 
from Ph.D.-12 library had a strong affinity for HNK20, while in the fourth eluate 70% 
of phages selected from the Ph.D.-C7C and 95% of phages from the Ph.D.-12 library 
showed high affinity (OD450 > 1 in ELISA).  
24 clones from each library, randomly selected from the second and third 
amplification or fourth elution, were further analyzed by an anti-IgG ELISA to 
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exclude false positives. No non-specific binding could be detected (data not shown), 
indicating that the peptides were binding to HNK20 paratope and not to other parts of 
the antibody like the Fc.  
Phage DNA from 12 ELISA-positive clones per library was extracted (2.4.4) and 
sequenced (2.2.2). Alignment of the aa-sequence revealed that 2 different peptide-
motifs had been selected. The 6 different sequences were arranged into 2 groups, 
according to the core motif they shared. Group “a” consisting of the clones H7A4, 
H12C2 and H12H2 contained a R/KxRxLxM motif, whereas group “b” consisting of 
clones H7A2, H12D3 and H12B3 contained a TxPxxxS motive (Table 3-4). 
Table 3-4: Comparison of HNK20 selected phage displayed peptides 
Group Clone # Frequency Sequence 
a) H7A4 1x   RIRNLLM 
 H12H2 7x   RIRNLLMKIPRE 
 H12C2 3x   KRRRLHMPRPRK 
 consensus  R/KxRxLxM 
 RSV-F aa132-148    KKRRFLGFLLGVGSAIA 
    
b) H7A2 10x    TKPLQKS 
 H12D3 1x    TKPLQKSPIHIL 
 H12B3 1x KKKTRPRMISQL 
 consensus     TxPxxxS 
 
The table shows the two different groups (a and b), the clone identification number, the frequency with 
which they were found within the 11 (H7) or 12 (H12) sequenced clones and their sequence. a) The 
R/KxRxLxM motif group might show some homology with the furin cleavage site II (KKRR) within 
the RSV-F sequence (aa 132-148) and the fusion peptide (FLGFLLGVGSAIA) b) The TxPxxxS motif 
shows no homology to the RSV-F sequence 
 
None of the sequences had high homology with the RSV-F sequence. However, some 
similarity of the R/KxRxLxM group with the furin cleavage site KKRR could be 
identified. 
All six clones (H7A2, H7A4, H12B3, H12C2, H12D3, H12H2) were further 
characterized. Phage particles from all clones as well the two libraries (as control) 
were amplified and purified (2.4.3.1). Serial dilutions of each phage preparation were 
tested in an HNK20 ELISA to determine the best binding peptides (Figure 3-12). All 
peptides demonstrated concentration-depending binding to HNK20. The peptide with 
the highest affinity was H12H2 followed by H7A4, both from the R/KxRxLxM 
group. Peptide H7A2, from the TxPxxxS group had the third highest affinity.  
The clones H12H2 and H7A2 were chosen to be further characterized by an RSV-F-
protein competition ELISA (2.4.5.3). Binding of both clones to HNK20 could be 
competed out by purified RSV (Figure 3-13). 
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Figure 3-12: Binding of selected clones to HNK20 
The figure shows the titration of HNK20 selected phages (2.4.1.) against HNK20 in an ELISA (2.4.5.) 
The different phages are shown at different starting concentrations. The amplified Ph.D.C7C and 
Ph.D.12 were used as control. The clone H12H2 showed the best binding properties, followed by 
H7A4. Both clones shared the same consensus motif (R/KxLxM). Clone H7A2 with the third best 
binding properties had a different binding motif (TxPxxxS).  
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Figure 3-13: HNK20 selected phages H12H2 (a) and H7A2 (b) in competition with RSV  
The figures show two HNK20 selected phages (H12H2; H7A2) from two different motif groups 
(RxLxM, TxPxxxS), in  competition with inactivated RSV. H12H2 (R/KxRxLxM) reached almost 100% 
competition at a RSV concentration of 5µg, indicating that H12H2 and RSV were competing for the 
same HNK20 binding site. 100% competition was not reached with H7A2 in the range of RSV 
concentration used, indicating that H7A2 was competing with RSV for HNK20 binding and performs 
better than H12H2 since H7A2 could not be competed within the range of RSV dilutions used.  
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The two phages and the corresponding peptides were also analyzed in a western blot 
(2.4.6) using HNK20 and anti-pIII antibody. The peptide-pIII fusion protein in both 
clones could be detected using HNK20 and anti-pIII antibodies confirming that the 
specific peptide presented on pIII conferred the HNK20 binding. Thus phage-
to the AlMV RNA3-based vector, pBR 
imics 
2x10 pfus/ml for H7A2 and 2.6x10 pfus/ml for H12H2 were obtained as determined 
presented peptides H12H2 and H7A2 were identified as mimics of the HNK20 
epitope, since they were recognized by HNK20 and competed with RSV for binding 
to the antibody.  
The two selected peptides were fused to AlMV-CP and recombinant virus particles 
were produced for potential mice immunizations. For this, the H12H2 dodecapeptide 
RIRNLLMKIPRE without the linker and the heptapeptide TKPLQKS preceded by 
AC and followed by CGGGS were cloned in
(2.2.1.3), sequenced (2.2.2), in vitro transcripts synthesized (2.2.4) and inoculated to 
P12 plants (2.3.1). Both constructs pBR-H12H2 and pBR-H7A2 gave mild symptoms 
in plants, mostly yellowing of the veins and mosaic pattern formation (data not 
shown). In an AlMV-CP Western blot recombinant CP could be detected in i- as well 
as in n-leaves, indicating that the virus could move locally and systemically. The 
peptides also were stably maintained after 14 dpi. However, due to the small size of 
the peptide it was difficult to differentiate the wt CP band and band from the chimeric 
CP containing the peptide. Chimeric AlMV particles could be purified (2.3.2) to a 
purity of 80% for AlMV-H7A2 and 90% for AlMV-H12H. This corresponds with 
yields of 12µg/g for pBR-H7A2 and 5µg/g for pBR-H12H2. It is possible that the low 
yields were due to high content of positively charged amino acids in the peptides that 
has been shown to affect chimeric virus production. This is an example of peptides 
that inspite of their small size, and ability to move systemically were difficult to 
purify from infected leaf tissue, probably they formed no viable particles.  
The chimeric particles obtained were then examined by Western blot analysis (2.4.6) 
and HNK20 ELISA (2.4.5.4). They failed in both assays indicating that the 
presentation on M13 phage pIII was critical for the correct conformation of the 
peptide. Consequently selected peptides did not maintain their properties as m
upon presentation on AlMV.  
M13 phages H12H2 and H7A2 were produced on a large scale (2.4.3.2.1) and 
purified by CsCl gradient centrifugation (2.4.3.2.2). Phage concentrations of 
14 14
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by spectrophotometrie (2.4.3.2.3). Immunization of mice (2.5.1) with these phage-
preparations failed to induce significant anti RSV-F-IgG response, although an anti 
characterized neutralizing abs can be used to select corresponding mimics which 
tigen [153]. In case of RSV Steward et al. (2001) report the 
ized by an RSV 
phage response could be detected (data not shown).  
3.2.2 Discussion 
HNK20 is a murine anti-RSV IgA neutralizing antibody that is known to prevent 
disease [114]. It has been humanized [113] and is under investigation for human 
trials. Its epitope however, is not known. Several reports have shown that well 
could then be used as an
identification of a peptide mimic selected using a neutralizing and protecting 
monoclonal antibody [150] that was further characterized as mimotope, because it 
induced cross-reactive neutralizing and protective antibodies [152]. This led to the 
development of a mimotope-based synthetic peptide vaccine [151].  
In this study 6 peptides were selected from 2 phage-displayed libraries. All the 
peptides were HNK20-specific. Among these peptides 2 motifs were identified of 
which one had a low level of homology to the second furin cleavage site and the 
fusion peptide in RSV-F protein. One peptide from each group (H7A2 and H12H2) 
that showed the highest affinity for the ab was further character
competition ELISA. Because these peptides competed with the natural antigen for 
HNK20 binding, they were considered to be true mimics. However, their antigenicity 
was lost upon sub-cloning the DNA sequence into the pBR vector and expression as a 
fusion with AlMV-CP, indicating that the pIII sequence environment contributed to 
their antigenicity or that the AlMV CP environment did not support the correct 
peptide conformation. Lost antigenicity of a peptide selected from a phage display 
library upon expression as AlMV-CP fusion was observed previously (Dr. Vadim 
Mett, personal communication).  Creation of a peptide library with AlMV-CP as the 
carrier molecule instead of phage should help overcome some of the problems 
associated with “context”. Since there are reports of successful immunizations with 
pIII-presented mimics [219, 220] or epitopes [221] larger amounts of phages H12H2 
and H7A2 were produced and purified for further immunological analysis. 
Immunization of mice with M13 pIII presented HNK20 mimics H7A2 and H12H2 did 
not produce any significant RSV specific antibody titers. However, an anti-phage 
response was detected in an anti M13 ELISA (data not shown) indicating that the 
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immunization itself was successful. The peptides H7A2 and H12H2 are therefore not 
mimotopes but mimics of the HNK20 epitope, since they are not immunogenic but 
only antigenic.  
Unfortunately, there is no established relation between the antigenicity of a peptide 
and its immunogenicity. El Kasmi et al. (1999) report an example in which only weak 
antigenic constructs with low affinity to the selecting antibody induced cross-reactive 
antibodies [222]. The discrepancy between the antigenicity and immunogenictiy of a 
peptide could be explained by any of the following: (i) that a truncated peptide, in 
oneal and subcutaneous route three times at two 
week-intervals with purified virus particles of AlMV-RSV-F-9-12, 14-16, 19-22, 26, 
. Control 
groups received AlMV-RNA3 particles or virus re-suspension buffer (called final 
ontrol and inactivated RSV as positive control. A separate group 
which the part responsible for immunogenicity is missing but antibody recognition 
sequences are present, (ii) the peptide is a true antigenic mimic but does not bind the 
same paratope as the natural epitope [203, 223] and therefore does not induce cross-
reactive antibodies or (iii) the peptide is not presented in the right conformation, 
which may play an even more important role in immunogenicity than in antigenicity, 
where antibodies can induce the appropriate conformation by induced fit [153].  
Additionally, the fusion of the peptide to the minor coat protein pIII, which is only 
present in one to five copies per phage particle, might be a drawback. Fusion to the 
major coat protein pVIII, that is present in 2700 copies per phage particle, could give 
more promising results [202, 203].  
3.3 Mice immunization and identification of RSV-F B-cell 
epitopes  
3.3.1 Results 
Mice were immunized by intraperit
27, 29-31 in presence of Freund’s complete and incomplete adjuvant (2.5.1)
buffer) as negative c
of mice were injected without adjuvant. The constructs included in this study were 
AlMV-RSV-F-9, AlMV-RNA3 and inactivated RSV. Serum samples were collected 
prior to the first and after the third injection. Anti RSV-F IgG titers were determined 
by ELISA using purified RSV as antigen (2.5.1.1). Values obtained from replicates 
were averaged and the pre-immune value subtracted.  
All AlMV-RSV-F constructs and the inactivated RSV generated anti RSV IgG 
response. Anti RSV antibody titers in presence of adjuvant were 10 times greater than 
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without adjuvant. Titers generated by RSV were greater than those generated by the 
chimeric AlMV-RSV-F peptide virus particles. Surprisingly, injection of AlMV-
RNA3 virus particles (control) gave a higher titer than the assay background, which 
aining five constructs reached their endpoint at a 
).  
was around 0.05 (data not shown). 
Detailed analysis of the anti RSV IgG titers generated by the AlMV-RSV-F constructs 
are shown in Figure 3-14 for a set of 3 dilutions. All constructs generated a specific 
RSV response, which was significantly greater than the AlMV-wt control up to a 
dilution of 1 to 200. At a dilution of 1 to 800 eleven out of sixteen constructs had 
reached their endpoint titer. The rem
dilution of 1 to 3200 (AlMV-RSV-F-22 and 27) or had endpoints below 3200, which 
were not further determined (AlMV-RSV-F-11/15/16).  
In an AlMV-ELISA (2.5.1.1) all AlMV-constructs gave high titers. Although free 
peptide was not included in the study it is expected that the titers will be greater than 
those with peptide alone, because of the presence of the AlMV virus particles as 
carrier molecules. No difference between the AlMV-RSV-F constructs and the 
AlMV-RNA3 control could be observed (data not shown
0
0.1
0.2
0.3
0.4
0.5
0.6
F-9 F-10 F-11 F-12 F-14 F-15 F-16 F-19 F-20 F-21 F-22 F-26 F-27 F-29 F-30 F-31
1 to 200
1 to 800
1 to 3200
 
 
Figure 3-14: Comparison of anti RSV IgG titers generated by AlMV-RSV-F constructs at 3 dilutions 
 
Anti RSV IgG response generated by 17 different AlMV-RSV-F constructs (AlMV-RSV-F-9-12, 14-16, 
19-22, 26, 27, 29-31) at three dilutions (1 to 200, 1 to 800, 1 to 3200). Up to a dilution of 1 to 200 
(AlMV-RSV-F9/20) all titers were found to be higher then the subtracted AlMV-RNA3 control. Nine 
constructs reached their endpoints at a 1 to 800 (AlMV-RSV-F 10/12/14/19/21/26/29/30/31), two at 1 
 3200 (AlMV-RSV-F-22/27 /16). 
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3.3.2 Discussion 
e 
 RSV antibodies contribute significantly to 
enerated at least 10-fold higher 
aa) and therefore presence of more 
 presented as KLH-conjugate. This correlates well with our 
associated with disease exacerbation [70, 116, 117, 143], but might be 
Antiviral antibodies exert activities against free virus and infected cells, whereby th
first can protect cells from viral infection and the latter mediate lysis of infected cells. 
By far the most desirable activity of an antibody is the neutralization of free virus in 
vivo although non-neutralizing abs also contribute to immunity. In both cases high 
affinity abs are desired (1.3.1). In case of
immunity, several neutralizing abs have been described of which some are used for 
passive immunization and disease treatment (1.2.3).  
All AlMV-RSV-F constructs generated RSV-F specific antibodies in the presence of 
adjuvant. The response was not significant in the absence of adjuvant, but it is 
expected that the titers attained might be greater than those with peptide alone, 
because of the presence of a carrier molecule. 
With and without adjuvant the carrier, AlMV-CP, g
abs titers than the presented RSV F derived peptides, when comparing RSV and 
AlMV ELISA results (data not shown). High responses against AlMV-CP might be 
explained with its approximately 10 times greater size of the protein (224aa), when 
comparing with the F derived peptides (24
epitopes. Nicholas et al. (2003) reported an approximately 10-fold higher response to 
the CPMV carrier than to CPMV presented peptides [26].  
The observed response obtained with the AlMV-wt control might be due to some 
cross-reactivity as observed by Olszewska and Steward [224]. However, since the 
AlMV-CP response was always less than for AlMV-RSV-F virus particles and 
reached background level after serum was diluted 1 to 200 it was not expected to 
affect the final result.  
Nicholas et al. (2003) report a marked TH1 biased immune response, as determined by 
a predominantly IgG2a isotype peptide-specific antibody response and the release of 
IFN-γ but not IL-4 or IL-5 from lymphocytes exposed to the CPMV presented peptide 
antigen in vitro [26]. In comparison they found a TH2 biased response (IgG1), when 
the same peptide was
ELISpot data, where no TH2 response was found (Table 3-6). Until now no TH2-
epitopes have been described for the F protein [225-227] and it is expected that 
peptides presented on chimeric plant virus particles would stimulate preferably a type 
1 response. In case of RSV this would be advantageous, since the type 2 response is 
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disadvantageous in cases where a type 2 response is needed. To further determine the 
possibility that plant virus presented peptides might bias the T-helper/B-cell response 
towards type 1, mice sera should be examined specifically for IgG2a and IgG1. 
Furthermore, known type 2 epitopes should be tested as AlMV-CP fusion to see if a 
type 2 response can be induced when the epitope is presented on the surface of AlMV 
particles.  
All AlMV-RSV-F constructs generated significant response with titers that ranged 
from 200 (AlMV-RSV-F 9/20) to over 3200 (AlMV-RSV-F-11/15/16). A sharp 
decrease in titers for AlMV-RSV-F-11 and a slower decrease for AlMV-RSV-F-15 
and 16 were observed. The former could indicate a higher antibody quantity with 
lower affinity, whereas the latter, a higher affinity and therefore a potential 
neutralizing epitope.    
Table 3-5: RSV-F B-cell epitopes described in literature and comparison with corresponding AlMV-
RSV-F constructs 
Literature AlMV-RSV-F 
RSV-F-residues RSV-F-residues 
Ref. 
First  Last  
# 
First  Last  
Sequence 
AlMV-RSV-F-construct/epitope 
[74] 173 182 10 166 189 KIKSALLSTNKAVVSLSNGVSVLT 
[92] 205 225 
[93] 221 232 13 
12 198 221 YIDKQLLPIVNKQSCSISNIETVIEFQQ 
[94] 214 237 ISNIETVIEFQQKNNRLLEITREF 
15 246 269 PVSTYMLTNSELLSLINDMPITND 
268 
285 NDMPITNDQKKLMSNNVQIVRQQS 
[97] 16 
 RQQS 
[95] 221 237 13 214 237 ISNIETVIEFQQKNNRLLEITREF 
[96] 262 
16 262 
262 276 262 285 NDMPITNDQKKLMSNNVQIVRQQS 
NDMPITNDQKKLMSNNVQIV[98] 265 272 16 262 285 
[95] 289 298 17 278 301 VQIVRQQSYSIMSIIKEEVLAYVV 
15 246 269 PVSTYMLTNSELLSLINDMPITND 
255 275 
16 
23 
262 285 
374 
NDMPITNDQKKLMSNNVQIVRQQS 
TLPSEINLCNVDIFNPKYDCKIMT Around 390 397 
[88] 
425 445 26 422 445 CTASNKNRGIIKTFSNGCDYVSNK 
[99] 483 488 29 470 493 KGEPIINFYDPLVFPSDEFDASIS 
 
 the co
.  T levant ature e first and st RS the 
-RS ru mber and first a st RS de in 
each construct. Bold numbers indicate constructs, for 
immunolog ivit e last mn ws an lay of  with 
scribed B-cell epi n b . 
Several RSV-F B-cell epitopes and antigenic areas are described in literature (Table 
-5). All of them are within the F1 part of the F protein in an area ranging from aa 173 
B-cell epitopes described in literature that overlap with rresponding AlMV-RSV-F constructs are 
shown he re  liter and th the la V-F-residue are indicated as well as 
AlMV V-F const ct nu  (#)  the nd la V-F amino acid residue of the pepti
which could be expressed 
 over
and were examined 
the AlMV-RSV-F peptide sequenceical act y. Th
tope (i
colu  sho
the de
 
old)
3
to aa 488, but mainly between aa 173 to aa 298 and aa 390 to aa 488. Nine AlMV-
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RSV-F constructs overlap these regions out of which six could be expressed and 
tested. It is therefore highly probable that n-abs were produced, especially those 
enerated by immunization with AlMV-RSV-Fg -15 and 16. This could be validated by 
r TH2 response can be identified. The first is 
characterized by secretion of IFN-γ and results in CTL activity besides some opsonic 
mp characterized by secretion of IL-4 
e assay takes thereby advantage of the fact that memory T-cell 
 cell by capture antibodies at the plate surface. Effector 
neutralization assays and viral challenge. These analyses have been performed but the 
data were not available at the time of writing this thesis. It would be interesting to 
screen promising AlMV-RSV constructs with sera from infected patients. Then, T-
helper cell mapping experiments should be performed with the PBMCs of the same 
patients to correlate the findings. AlMV-RSV-F-26 and 29 are likely to contain both 
B-cell and T-helper cell epitopes (3.4) 
3.4 Mapping of RSV-F CD4 epitopes 
B-cells and cytotoxic T-lymphocytes are the mediators of viral immunity. For 
complete functionality they need activation signals provided by T-helper cells, which 
themselves are activated through APCs, especially DCs (1.3). Depending on the 
composition of those signals a TH1 o
or co lement fixing ab production. The latter is 
and IL-10 among other molecules and results in a strong antibody response as well as 
eosinophilia (1.3.2). In case of RSV the TH2 response was found to cause disease 
exacerbation (1.2.3). 
In this study we generated a CD4+ de novo response using DCs (1.3.3) to capture, 
process and present ag. After a T-cell expansion period of 7 days in absence of 
antigen presenting cells were restimulated and tested for IFN-γ or IL-10 secretion in 
an ELISpot assay (2.5.2).  
In ELISpot assays the production and release of effector molecules like ILs and IFNs 
is measured [228]. Th
populations do not secrete effector cytokines until they are stimulated by the correctly 
presented ag. Cells are plated and test-antigen is added to allow possible secretion of 
effector molecules. As these molecules are secreted, they are captured in the 
proximity of the secreting
molecule dilution, degradation or binding to target receptors is thereby prevented. In 
this way, any spot forming cell (SFC) leaves a trace of its secretory activity [228]. 
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Furthermore, ELISpot assays are one of the few methods that can be performed with 
cryopreserved PBMC samples, allowing its use in a routine manner [229].   
The presented data document that AlMV-CP presented RSV-F-peptides can be used 
to generate an RSV-F specific T-helper cell response (3.4.1.1., 3.4.1.2.). Furthermore 
we analyzed, (i) which peptides gave a response and are therefore likely to contain 
RSV specific T-helper cell epitopes (3.4.1.2), (ii) if the response was of type 1 or 2 
(iii) if the response was consistent within different HLA-DR types (3.4.1.2.) and (iv) 
tion of the cells and used for low to 
intermediate resolution HLA A, B and DR locus typing. All HLA-types could be 
iven in Table 3-6 I. The 5 selected individuals (BC 072303, BC 
t HLA-DR 1, 4, 7, 9, 
MV-RSV-F-26/27/28) two times, which made the 
how these findings correspond to published results (3.4.2.1.) or those predicted in 
silico by the three different algorithms (3.4.1.3.).  
3.4.1 Results 
3.4.1.1 Preparation of PBMC cells, cell culturing and viability 
Human peripheral blood mononuclear cells (PBMC) were generated and stored as 
described (2.5.2.1). DNA was prepared from a por
determined and are g
080703, BC 091003, BC 101503, BC 110603) cover 12 differen
11, 12, 13, 15, 18, 51, 52 and 53, which are represented in approximately 90% of the 
Caucasian population [230, 231]. A more precise typing allowing the unambiguous 
identification of specific alleles, i.e. HLA-DR-0401 or 0404, was not performed. 
However, each assigned allele could represent anyone of a number of highly related 
alleles. i.e. HLA-DR 1 was typed 01GK, which included DR 0101, 01021, 01022, 
0104, 0105, 0106, 0107 and 0108. 
Cells were cultured and incubated with chimeric AlMV particles as described 
(2.5.2.3) and their viability determined after 3 and 10 days. In general cell viabilities 
of above 90% were reached, which corresponded well with that of the untreated 
control (95%). However, cell viability of pool B (AlMV-RSV-F-3/4/5) was constantly 
low (~50%) and that of pool F (Al
final ELISpot assay for BC 072303 and BC 110603 difficult. Reduced cell viability 
was probably due to contamination or impurity of some of the batches of purified 
AlMV particles and could not be assigned to a specific peptide. Significant 
differences in viability were also found between cells from different individuals, i.e. 
BC 091003 had an average viability of ~80%.  
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3.4.1.2 IFN-γ and IL-10 ELISpot analysis of AlMV-RSV-F-constructs 
In order to allow the analysis of all available 22 AlMV-RSV-F-constructs, constructs 
were assembled in 7 pools, representing stretches of expressible peptides (2.5.2.2). 
IFN-γ and IL-10 ELISpot assays were conducted as described (2.5.2.5). Untreated 
ells as negative control or those treated with Concanavalin A (ConA) or 
Phytohemagglutinin (PHA) as positive controls, were used to confirm cell viability 
and assay functionality (Table 3-6 II, III). In the IFN-γ ELISpot assay, the detected 
TH1 response of the AlMV-wt gave a low count of ~ 50SFC/10e6 cells (Table 3-6 II, 
III). Based on the AlMV-wt counts 3 different thresholds were calculated for each 
donor and assay to allow discrimination between positive and negative results (data 
not shown). For the following analysis the high threshold used by Karlssson et al. 
(2003) was applied, which considered numbers of SFCs as positive results if higher 
than the mean AlMV-CP count plus two times its Standard Deviation or  50 SFC/106 
(Table 3-6 IV). This high threshold allowed unambiguous differentiation between 
AlMV-wt and positive results.  
All donors responded to pool A, 4 out of 5 to peptides present in pool D and G, 3 to 
pool E, 2 to pool F and 1 out of five to pool B. No reaction was obtained against 
peptides present in pool C (Table 3-6 II). Based on the data obtained from BC 
080703, constructs from the three pools A, D, and G, that gave the highest results, 
were analyzed individually. From pool A construct AlMV-RSV-F-24 was identified 
as responsible for the positive result. AlMV-RSV-F-14 from pool D and AlMV-RSV-
F-31 from pool G. AlMV-RSV-F-24 gave a positive result in cells from all donors, 
AlMV-RSV-F-14 in 4 and AlMV-RSV-F-31 in 3 out of 5 donors. AlMV-RSV-F-
26/27/29 and 30 gave positive counts in some of the donors (Table 3-6 III). 
The IL-10 ELISpot assay, used to determine a TH2 response, gave no positive result in 
any tested AlMV-RSV-F construct (data not shown). To further confirm this result an 
IL-10 ELISA was performed using cell supernatants, which also gave no results 
(2.5.2.6) (data not shown).   
 
c
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Table 3-6: IFN-gamma ELISpot characterization of RSV-F derived peptides presented on AlMV-CPa
 BMC ± S.D.(II, III)  HLA type (I); mean number of SFC per 10e6 P
and threshold value (IV) 
 
HLA type (I) AlMV-RSV-F 
Pool (II) 
Threshold (III) 
constructs in pools (II) 
or individual (III) BC 072303 BC 080703 BC 091003 BC 101503 BC 110603 
I HLA-A  11, 80 2, 74 36, 36 74, 74 30, -b
 
 , 53 
II 
HLA-B  18, 55 57, 72 7, 44 18, 72 35, 42 
HLA-DR  7, 12 1, 11 4, 15, 51, 53 1, 13 9, 18, 52
 Neg. c 0 ± 0 113 ± 130 0 ± 0 0 ± 0 3 ± 6 
 
 
 
 
 
 1 
 5 
 
 
III 
 Pos. d 1502 ± 1630 1800 ± 386 2830 ± 100 2040 ± 660 4586 ± 558 
 AlMV-wt 23 ± 19 115 ± 48  39 ± 64 45 ± 61 17 ± 20 
Pool A 1, 24 118 ± 95 1170 ± 304 126 ± 205 296 ± 66 305 ± 180 
Pool B 3-5 63 ± 21e 8 ± 10 64 ± 62 12 ± 18 52 ± 56e
Pool C 9-12 0 ± 0 78 ± 60 40 ± 36  32 ±29 10 ± 18 
Pool D 14-16 180 ± 120 1728 ± 305 40 ± 60  253 ± 101 297 ± 13
Pool E 19-22 477 ± 270 343 ± 138 76 ± 54 46 ± 25 465 ± 28
Pool F 26-28 NDf 743 ± 232 98 ± 126 410 ± 60 NDf
Pool G 29-31 0 ± 0 1163 ± 337 198 ± 225 212 ± 94 70 ± 45 
 Neg. g  0 ± 0i (73 ± 75) j 0 ± 0  
 
 
 
 
 
 3 
 1168 ± 767 ND 3 ± 5 50 ± 40 1050 ± 1081 
 5 ± 8 ND 5 ± 6 286 ± 209 1518 ± 508 
 
 
 
 
IV 
 AlMV-wt h  0 ± 0 7 ± 16 10 ± 15  
 1 ND 44 ± 26 ND ND ND 
 14 350 ± 528 296 ± 77 13 ± 19 370 ± 290 650 ± 279 
 15 ND 8 ± 18 ND ND ND 
 16 ND 6 ± 14 ND ND ND 
 24 167 ± 136 130 ± 67 245 ± 199 120 ± 20 245 ± 15
 26 
 27 
 28 0 ± 0 ND ND 7 ± 12 17 ± 32 
 29 0 ± 0 1 ± 4 110 ± 167 ND 46 ± 32 
 30 0 ± 0 25 ± 12 160 ± 117 ND 18 ± 17 
 31 0 ± 0 73 ± 18 102 ± 87 388 ± 68 18 ± 15 
Threshold  61 211 /  50 167 / 50 167 / 50 57 
 
a)All constructs were tested at a concentration of 10 µg/ml in a 48h ELISpot assay after the generation 
of a de novo response using whole PBMCs from healthy adult blood donors. Measurements were 
performed at least in triplicates. No. of spots per 106 PBMC are presented 
I) Results of HLA A, B and DR locus typing. All HLA-DR types most frequently expressed in the 
Caucasian population are covered [230]. b) Could not be determined 
II) ELISpot results screening 7 AlMV-RSV-F construct pools; the pool composition is 
c)
indicated in 
e positive as well, are shown in bold italic. 
I) ELISpot results screening selected individual constructs. g)If different from negative control in II. 
h)If different form AlMV-wt in II. i)Screening of individual peptides for BC080703 was 
performed using the recall protocol, which lacked the 7days T-cell expension. j)Was not 
considered since AlMV-wt showed a much smaller and less variable value. Positive values are 
shown in bold.  
IV) Threshold: Results were considered positive if higher than 50 SFC/106 and/or the mean SFC-
AlMV-CP count plus two times its S.D. [232].  
the next columne. Negative control: un-stimulated cells were used that were treated the same 
way as the stimulated ones. d)Positive control: cells were stimulated with Concanavalin A. e)For 
BC 072303 and BC 110603 Pool B was tested without construct AlMV-RSV-F-3. f)For BC 
072303 and BC 110603 Pool F could not be tested since cell viability was to low, probably due to 
a contamination in the AlMV-RSV-F-28 batch. Therefore the individual constructs 26, 27, and 
28 were analyzed separately (see below). Positive values are shown in bold. Values below 
threshold (IV), but likley to b
II
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3.4.1.3 Analysis of AlMV-RSV-F-constructs in silico 
Two sets of -F-constru
ito lgori r ep PE .
d [208] s based on an alg  deve by H r et a , 210
ialize  on CD4+ epitope iction. s a vi x oach t
ased on “poc rofiles”. Most t H ro di
cal and racteristics ent a ch R p
e chara ized by "pock iles, uantit epre n o
tion of ino acid residu g cke  n
ndent o remaining HL R eft. ori ws icti
d range LA-DR type nkPep s on  sc
atrix. Each the result f an align of at  pept uenc s of 
edium or high affinity and yields an optimu nce ves t st 
ore RankPep has incorporated a  that evaluates if a 
ro in tio  t eas
 based on m matrice ed 
nd n poo ing  it is 
 in vitro, that com s both R b d ide clea
t set at contained AlM RSV-F-9/10/11 and 12, was used as negative 
control, since none of the peptides gave a positive count in the corresponding ELISpot 
t in the corresponding 
analy i 3 and BC 091003. An 
prog
each
Valu
those of pPeps are presented (Figure 3-15) and used for all further analysis. 
best 
majority of RSV-derived peptides (pPep and cPep) were found below rank five and 
AlMV-RSV
pe prediction a
cts were analyzed in silico using the freely 
available ep thms ProP ed, RankP  and SYF ITHI (2.5 3). 
ProPre  i orithm loped amme l. [209 ] that 
has spec d  pred It use rtual matri  appr hat is 
b ket p pockets in he human LA-DR g ove have stinct 
chemi size cha in differ HLA-DR lleles. Ea HLA-D ocket 
can b cter et prof " a q ative r sentatio f the 
interac  all natural am es with a iven po t that are early 
indepe f the A-D  cl  This alg thm allo the pred on of 
a broa  of H s. Ra  [211] use  a positi  specific oring 
m matrix is o ment least 5 ide seq e
m m seque  that gi he highe score. 
Furtherm cleavage algorithm
peptide is likely to result f m prote degrada n within he prot omes. 
SYFPEITHI [212] finally is an algorithm otif s deduc from 
natural ligands by single ligand analysis a Edma l sequenc , thus based 
on data generated bine  HLA-D inding an pept vage.  
The firs th V-
assay (Table 3-6). The second set, AlMV-RSV-F-14/24/29/30/31, was used as 
positive control, since these peptides gave a positive resul
ELISpot assay. Four HLA-DR-types (HLA-DR-0101/0404 and 1101/1501) were 
zed corresponding with the two ndividuals BC 08070
analysis of more alleles was not possible since they were not available using these 
rams. From the obtained peptide rank-list the inverse rank was calculated for 
 peptide (2.5.3.2).  
es of pure RSV-F peptides (pPep) and of chimeric peptides (cPep), if higher than 
Interestingly, only six peptides were ranked first or second, thus were predicted as 
possible binders within the whole RSV-F-peptide-AlMV-CP sequence; the 
thus had predicted binding properties similar or below AlMV-CP derived peptides. 
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0.1 (Rank ten) were considered positive. Four HLA-DR-types were analyzed
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SV-F-14/24/29/30 and 31 the positive one; based on the ELISpot data gener
/29/30/31 were positive for DR4 and 15.  Per HLA-DR-type pPep results are 
 the pPep results. Thus every cPep bar indicates a peptide in which the flan
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Table 3-7: Top ten ranked HLA-DR binding pepitdes as predicted by ProPred, RankPep and 
SYFPEITHI for HLA-DR 1/11/4/15 
Construct Program HLA-DR Ranka Sequence % oreSc
ProPred 0101 8           FSVNAG 3 VTT 7.
SYFPEITHI 1101 1 MSRLLEITREFSVNA  
 0404 6 MSRLLEITREFSVNA  
  6    LLEITREFSVNAG  
 1501 2                 VDSS  
PBR-RSV-F14 
  8    LLEITREFSVNAG  
ProPred 0404 8        IMTSKTDVS .5 
VT 
 TT
VT 
 
PVSTYML SQ 
20
RankPep 0101 7   KYDCKIMTSKTDVS .5 
  8                 VDSS .3 
 0404 5      CKIMTSKTDVS .8 
PBR-RSV-F24 
SYFPEITHI 0101 9.5                 VDSS  
ProPred 1501 1        INFYDPLVF .1 
S 
SSV
SSV
SSV
 
20
S 20
27
S 
55
ITSLGAI
I 
ITSLGAI
  3       IINFYDPLV .0 
RankPep 1501 8     EPIINFYDPLVF .3 
SYFPEITHI 0401 10             PLVF V  
  10                 VDSS  
 1501 2     EPIINFYDPLVF  
PBR-RSV-F29 
  8    GEPIINFYDPLVF  
RankPep 1101 2             NEKI V .0 
42
22
SQ 
19
PSD
PSD
 SD
PSD
PS 
NQS
 
EFDASIS
EFDASIS
 
LAFIRKS
 0401 7 MSDEFDASISQV .0 PBR-RSV-F-30 
SYFPEITHI 1501 7             NEKI  
ProPred 1106 5              LHN .1 
23
24
NQS
VNA
LAFIRKSV 
GKS 
 0401 9             LLHN .1 
RankPep 0101 8   SLAFIRKSDELLHN .0 
 0404 7         KSDELLHN .4 
SYFPEITHI 0101 4           DELLHN  
PBR-RSV-F-31 
  1101 8 MSSLAFIRKSDELLH  
VNA
V 
VNA
VNA
GK 
GKST 
GKSTTN 
17
15
21
 
Table of all pBR-RSV-F-14/24/29/30/31 derived peptides that obtain  thus 
considered potential HLA-DR binders. Shown are: the constructs nam e
for prediction (ProPred [208], RankPep [211] and SYFPEITHI [212]); pe (0101, 0401, 
1101, 1501); the rank of the predicted peptide; a for SYFPEITHI the m n icted 
binding sequence, contributing pBR-vector aa (MS and VDSSSQ) are shown in bold; the % score in 
relation to the best possible binder known by the program used.   
 
Since a success rate of approximately one to ten was described in the literature [233, 
234] peptides up-to rank ten were considered positive and are shown in detail in 
(Table 3-7). 
A comparison of the three different programs regarding their capacity to distinguish 
between positive and negative tested peptides is shown in (Table 3-8). Only RankPep 
distinguished clearly between positive (8 hits) and negative sets (2 hits). SYFPEITHI 
had equal amounts of hits (pos. 13, neg. 14) and ProPred found even mo l 
epitopes within the negative group (pos. 6, neg. 15). This tendency persisted even if 
ed a
e (c
 the
ean
 top 10 rank
onstruct); th
 HLA-DR ty
 rank is show
and were 
 program used 
; the pred
re potentia
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only the top five ranked peptides were considered. The average rank of a positive 
n that of the negative peptides. However, this tendency 
ist i ntage of score reached (%
which is calculated based on the best possible binder known by the program, was low 
t e predicted de ers to the tested HLA- R 
molecules.  
Table 3-8: Comparison of ProPre Pe nding prediction result
peptides that wer tive tive t
# peptides 
peptide was slightly higher tha
was not stat ically sign ficant. The average perce  score), 
indicating tha  th  pepti s are not optimal bind D
d, Rank p and SYFPEITHI peptide bi s from 
e tested posi  or nega  in he in vitro assay. 
Program pos/neg Top 1 p 5 co
2 17.7
0 To  # cPep Mean rank Mean % s re 
pos 6  0 5.7 +/- 3.2 27.8 +/-  ProPred 15 5 .7 22.5 +/- 12
os 8 2 2.1 13.4 +/- 11
neg 1 7.2 +/- 2 .1 
p 3 6.5 +/- .5 RankPep 2 0 18.2 +/- 8
 4 
neg 2 7.5 +/- 0.7 .2 
pos 13 7 6.3 +/- 3.1 n.a. Syfpeithi neg 14 7 4 5.6 +/- 2.3 n.a. 
 
Shown are the algorithm used (Program; Pro d FPEITHI [212]). HLA-DR 
binding propertie lyze es d within
rank ide p
e ea S.D.. Th
compares the obt th st p i  binder kn n. 
For SYFPEITHI ore  av
 
pos qu he program
able to predict  generated results. However, RankPep predicted truly the 
inding behavior for 4 out of 5 sequences (AlMV-RSV-F-24/29/30/31), whereas 
me aa-sequence within the 24mer peptide, which allowed the deduction of the 
art of the epitope in 1/3 of the in silico predictions (Table 3-7). 
the result of a TH1 response, which is obtained upon recognition of viral peptides in 
Pre  [208], RankPep [235], SY
s of the ana
e top 5, 
d peptid (pos/neg), the number of peptides identifie
mber of chimeric RSV-F 
 the top 
10, respectively t
contributing to the t
h ed pept s (# peptides), the nu eptides 
e l ter op 10 (# cP
ained score wi
p), the m
 the be
n ra
oss
nk +/- S.D. and the mean % score +/- 
ble score (100%), reached by the best
at
ow
a % mean sc was not ailable (n.a.). 
 
Detailed analysis of the itive se ence set revealed that none of t s were 
 the in vitro
b
SYFPEITHI and ProPred identified correctly 3 (AlMV-RSV-F-29/30/31 and AlMV-
RSV-F-14/29/31 respectively) (Table 3-7). Even if most of the predicted peptide 
sequences were not identical between different programs and alleles, they covered the 
sa
potential CD4 epitope sequence. Surprisingly, a significant contribution of the N- and 
C-terminal flanking aas, that are derived from the pBR vector (Figure 3-2), were 
found to be p
3.4.2 Discussion 
An appropriate T-cell response against RSV is crucial for the efficient clearance of 
virus from the infected lung. Such a response consists of CTL activity and IgG 
secretion, which are both initiated and maintained through IFN-γ. IFN-γ production is 
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an MHC II context through the TCR of CD4+ cells (1.3.2). There is limited 
knowledge on i) which RSV-F peptides are presented, ii) what kind of MHC II alleles 
present them, and iii) if such MHC class II peptides stimulate a TH1 or TH2 response. 
In this present study, the ability of AlMV presented RSV-F-derived peptides to 
generate a CD4 T-cell response was evaluated, and the system was also used to map 
potential T cell epitopes (3.4.1.1). Furthermore these peptides were characterized 
using a panel of donors that together covered the most frequently occurring HLA 
dditionally our findings were 
c w  g sili in alua nt 
epitope prediction algorithm
3 app  RSV  CD4 topes in vitro
W hole Cs f  five healthy donors to generate and characterize an anti-
viral CD4-T-cell response following a protocol that consisted of a five day priming 
ere generally well tolerated; however some construct pools (B, F) gave reduced 
bserved, 
ight therefore be possible that wells in which few 
class II haplotypes within the Caucasian population. A
ompared ith those enerated in co, allow g us to ev te three differe
s (3.4.1.3).  
.4.2.1 M
e used w
ing of -F epi  
 PBM rom
phase, and a T-cell expansion period of seven days (3.4.1.1) before quantifying the 
IFN-γ and IL-10 response directly through an ELISpot assay (2.5.2.5). A protocol 
without T-cell expansion used by van Bleek et al. (2003) was also tested but 
generated a measurable response only in 1 out of 5 donors (2.5.2.4). AlMV-constructs 
w
viability, which in some cases made further studies impossible (3.4.1.1). This toxicity 
was not construct but batch-specific, indicating that there was variability between 
batches of purified virus.  
Quantifying IFN-γ and IL-10 responses directly through ELISpot assays (2.5.2.5) was 
the method of choice when compared with Flow Cytometry. However, high variations 
within the replicates were obtained for all tested pools, peptides and controls. This 
might be a combined result of uneven distribution of cells and antigen as well as an 
over or underestimation of spots using the acquisition software. To adjust for possible 
errors and to allow statistical analysis measurements were performed at least in 
triplicates. Also striking differences in cell spot shape and intensity were o
which could not be considered. It m
but strong spots could be observed generated more IFN-γ than many small SFCs.  
ELISA analysis could be used to determine how much cytokines were secreted.  
Applying stringent data evaluation protocols was important to identify positive pools 
and peptides. A variety of protocols are described in literature ranging from low to 
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high thresholds [77, 101, 232, 236]. In the assays performed a high threshold value 
was selected, which consisted of the SFC count of AlMV-wt plus two times its S.D or 
50SFCs. AlMV-presented RSV-F derived peptides were found to give an IFN-γ but 
not an IL-10 response in all donors (3.4.1.2). This corresponds well with the finding 
that the F protein has been described to contain multiple CD4 epitopes responsible for 
most of the CD4 responses [100, 101].  
Detailed analysis revealed that for each donor at least one (BC091003) and up to 5 
(BC070803) pools contained positive peptides. Analysis of the three most common 
pools A, D and G starting with Donor BC080703 clearly identified AlMV-RSV-F-
14/24 and 31 as major antigenic constructs, out of which the peptide in AlMV-RSV-
 successfully produced and tested 20 of the described 31 
leek 
F-24 could be identified as a possible universal epitope, giving a positive response in 
all donor cells tested. AlMV-RSV-F-14 gave a positive response in 4 out of 5 donors. 
AlMV-RSV-F-31 was found to be more HLA restricted (Table 3-6). AlMV-RSV-F-1, 
which was part of pool A but gave a 3 fold lower response then AlMV-RSV-F-24 and 
was not further analyzed, might contain potential CD4 epitopes. Constructs in pools E 
and F, which gave positive results, were not individually analyzed.  
So far only two attempts have been made to map RSV-F CD4 epitopes [100, 101]. 
Van Bleek et al. (2003) used synthetic peptides (18mers, 12 aa overhang), PBMC 
from healthy donors, a 24h recall protocol, ELISpot assays and a low evaluation 
threshold [101]. 31 CD4 epitopes were identified (Table 3-9). Using AlMV presented 
RSV-F derived 24mers we
synthetic peptides. The remaining 11 synthetic peptides were located either within the 
signal peptide or within areas that could not be expressed. A detailed comparison of 
our findings and those of van Bleek et al. is shown in Table 3-9. Nine of the twenty 
18mers are completely contained within the AlMV-RSV-F-24mers; four are 
shortened by one, five by three and two by five aas. Truncations up to 3 aa are 
tolerated by the MHC II since it is insensitive to frame shifts and off-sets of 3 to 4 aas 
[228]. The AlMV-based peptide library thus seemed to include the vast majority 
(90%) of potential epitopes described by van Bleek et al.   
Besides AlMV-RSV-F-10, AlMV-RSV-F-11/12 and AlMV-RSV-F-28 for which we 
could not detect a positive response, our results correlate well with those of van B
et al. (2003), with minor differences regarding the HLA restrictions. Differences 
might be explained with truncated peptides and or different HLA-types. 
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Table 3-9: Comparison of IFN-gamma ELISpot results with van Bleek et al. (2003) 
HLA-DR-Restriction Synthetic pept AlMV-CP-
 
ides 
(18mers) presented peptides (24mers) 
-F-
ues # 
RSV-F-
residues 
RSV-F-Peptide Sequence 
(18mers in bold) 
42 1 22-45      FASGQNITEEFYQSTCSAVSKGYL 
101503
01 
13 
of data:
Peptide/
Pool 
080703 091003 072303 110603Taken from 
van Bleek 
et al. 
01 
11 
04 
15 
07 
12 
09 
03 # 
RSV
resid
5 25-
Source 
6 31-
10 55-
*0401 
*0701 +  +++ +
*0701 
 + A 
48 1 22-45      FASGQNITEEFYQSTCSAVSKGYLSAL 
72 3 54-77      TSVITIELSNIKENKCNGTDAKVK 
13 73-
14 79-
15 85-1
30 175-
90 4 70-93      NGTDAKVKLIKQELDKYKNAVTEL 
96 4 70-93      NGTDAKVKLIKQELDKYKNAVTELQLL 
02 5 86-109     KYKNAVTELQLLMQSTPPTNNRARR 
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Interestingly, the AlMV presented peptides were found to be less HLA restricted. For 
 peptide 66 (from the van Bleek study) was found to give an HLA-DR-0401 
 response, whereas the corresponding construct AlMV-RSV-F-24, gave a 
response in all donors. W  determ
84/AlMV-RSV-F-31 were found to be DR-04/15- and DR-01-restricted
In order to exclude any possible CTL activity, that m nd
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es. Fu ermore it would be of great interest to map possible CTL epitopes using 
 of e rimental setting but whol BM n
milar to Brandenburg et al. (2000) [76].  
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gives a response then we can conclude that peptides presented on AlMV CP 
contributed to the response or might be solely responsible for it. This would answer 
question two. 
Numerous reports have described the successful use of prediction programs to 
determine T-cell epitopes [233, 234, 237, 238]. Here we found the T-helper cell 
ici et al. (1999) for the prediction of a T-
helper cell epitope [234]. At the current accuracy it is unclear if in silico epitope 
epitope prediction programs that we used were not very accurate. Peptides that tested 
positive in in vitro tests were normally found within top ten ranked peptides in in 
silico prediction. Thus the success rate could be estimated as 1 to 10. A similar rate 
was described by Zhong et al (2003), who found 16 positive out of 101 predicted CTL 
epitopes using RankPep [233] and by Man
prediction is advantageous in screening synthetic or peptide libraries. CD4 epitope 
prediction remains computationally challenging, due to the nature of the MHC II. Not 
only the variable peptide ligand length but also the degeneration of binding motifs 
between different alleles causes difficulties [164]. HLA-DR 0405 for example has a 
defined binding motif whereas HLA-DR 0401 accepts almost all aas in its anchor 
positions [212]. The increasing number of different HLA-DR alleles hampers precise 
prediction since few allele-specific matrices are available and/or the precise 
identification of donor HLA types is very elaborate. However, these obstacles can be 
overcome and in silico epitope mapping could then play an important role in the high 
throughput and genome-wide characterization of T-cell epitopes.  
 4 Summary and Conclusion 
4.1 Sum
 
mary 
Positively charged peptides and resulting chimeric C
significant higher than wt, were found to be difficult or
was probably due to insufficient particle formation and a
HR (3.1.2.1). The performance of these constructs was
acidic amino acids that compensated the positive cha
hydrophobicity decreased chimeric particle product
contained more hydrophobic then polar aas were diff
could be explained by the affinity of the hydrophobic p
and consequently their loss in the membrane fraction 
virus purification (3.1.2.1). Compensating the hydroph
amino acids did improve the performance (3.1.1.6.2).  
Plant viruses have gained sustainable interest as presen
for immunogenic peptides within the last decade [7, 8] 
vaccines has become an increasingly viable propositio
immunogenic peptides, toxic or immune-pathologic 
exacerbation as seen for the first RSV vaccine, could b
peptide vaccines have the potential to generate periphera
administered appropriately [9]. Finally, the ease of pa
and scale-up, enhanced peptide immunogenicity and s
very promising tool in vaccine development. 
In this study it was investigated if Alfalfa mosaic virus c
RSV-F-derived peptide library, (ii) phage-selected mim
fusion inhibitors. The library was then used to screen fo
data obtained was used to establish AlMV as a scr
performance in different applications. This is the first st
been used to identify potential B and T-helper cell epitop
Based on the performance of different AlMV-RSV-F 
identified that influenced recombinant peptide express
fusion: (i) charge, (ii) hydrophobicity and (iii) size.  Before I came here I was confused
about the subject. Having listened
to your lecture, I am still confused
– but at a higher level.
Enrico FermiPs that had a charge and pI 
 unexpressible (3.1.1.5). This 
 resulting induction of a plant 
 improved by the addition of 
rge (3.1.1.6.2). High level of 
ion as well. Peptides that 
icult to purify (3.1.1.5). This 
eptides for the cell membrane 
during sample preparation or 
obic amino acids with polar 
tation and production systems 
and consequently their use as 
n.. By the display of specific 
responses, such as disease 
e avoided. Furthermore, these 
l and/or mucosal immunity, if 
rticle production, purification 
tability, makes this system a 
ould be used to present (i) an 
ics and (iii) anti-viral peptide 
r B- and T-cell epitopes. The 
eening tool and evaluate its 
udy in which a plant virus has 
es for vaccine development.  
constructs three factors were 
ion as N-terminal AlMV CP 
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ould be used to display a defined, 
cts could be easily expressed and 
r modification of the overall charge or hydrophobicity of 
l express, present and deliver known B-
pecific IFN-γ response in one or 
The results of the present study showed that AlMV c
RSV-F derived peptide library. 65% of the constru
purified, while after furthe
the foreign peptide efficiency levels of up to 80% of might be reached. Thus, the 
yields and efficiency of expression and virus particle purification can be improved by 
adding amino acids that balance out the charge or hydrophobicity. The results from 
this study could help develop an improved AlMV-based expression vector.  
Two phage-displayed random peptide libraries were successful screened for HNK20 
binders. Several different phages showed good binding properties to HNK20 
antibodies and two of them competed with RSV for binding (3.3.1). However, these 
properties were lost after expression of the mimics on AlMV particles (3.2.2). 
AlMV CP has already been used to successfu
cell epitopes from various pathogens including rabies virus [9, 10, 25, 41], HIV [9] 
and RSV [24]. Furthermore, we have shown that all RSV-F derived constructs tested 
in mice generated a specific RSV IgG response out of which six covered known 
neutralization sites and are therefore likely to generate neutralizing abs (3.3). Further 
studies have to be undertaken to determine whether neutralizing abs were generated 
and if, as yet unknown, neutralizing epitopes could be identified.  
Chimeric AlMV particles were also successfully used as presentation, delivery and 
screening tool for T-helper cell epitopes using human dendritic cells for the assay. Out 
of a pool of 22 constructs at least 6 gave an RSV-F s
more different donors (3.4.1). AlMV-RSV-F-24 (aa 390-413) gave a potential 
universal TH1 response when tested in 5 different donors, that covered the most 
common HLA-DR-types in the Caucasian population. Several other peptides also 
gave an IFN-γ response. Our findings correlate well with those described in literature 
[101], thus indicating that the AlMV-CP presented RSV-F- derived peptides are 
processed correctly. No TH2 response could be detected (3.4.2), although it is possible 
that peptides presented on AlMV surface could have a TH1 bias. A comparison of the 
in vitro data with those generated in silico revealed that none of the programs used 
was able to predict T-helper cells correctly. However, consensus sequences of 
potential epitopes within the 24mer could be identified.  
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4.2 Conclusion 
The results of the research helped to establish Alfalfa mosaic virus as a peptide 
expression, presentation and delivery system and as a screening tool to identify 
potential B- and T- cell epitopes for vaccine development. The findings identified the 
nature of peptides that were expressed well in the AlMV system and provide possible 
modifications to improve the efficiency with which different peptides can be 
 HLA-
expressed on the surface of AlMV using the currently available vector.   
AlMV presented RSV-F derived peptides elicited a specific RSV-F IgG response in 
mice upon immunization. AlMV-RSV-F-24 (aa 390-413) gave a potential universal 
TH1 response when tested in 5 different donors that covered the most common
DR-types in the Caucasian population. Further immunological studies need to be 
performed. The results of this study will help to identify potential vaccine candidates 
that can be used to produce a safe and effective peptide-based vaccine against RSV.  
With this and other studies AlMV has been established as an important front-runner in 
plant-based peptide presentation systems, besides CPMV, PVX and TMV. 
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 7 Appendix 
7.1 List of abbreviations 
   adenine 
ies 
-bromo-4-chloro-3-indolyl phosphate 
aMV   Cauliflower mosaic virus 
 Canine parvovirus 
TL   cytotoxic T-Lymphocyte 
MSO   dimethylsulfoxide 
 
Everything you always
but were afrai
Woody Allen
 wanted to know about…
d to ask.
°C   degree Celsius 
%   percentage 
A
aa   amino acid(s) 
ab, abs   antibody, antibodies 
n-ab, n-abs  neutralizing antibody, neutralizing antibod
Amp   ampicillin 
AlMV   Alfalfa Mosaic Virus 
AP    alkaline phosphatase 
APC   antigen presenting cells 
A. tumefaciens  Agrobacterium tumefaciens 
BC   buffy coat 
BCIP    5
BNYVV  Beet necrotic yellow vein virus 
bp    base pair 
BSA    bovine serum albumin    
C    cytosine 
C
CD   cluster of differentiation 
CMV   Cucumber mosaic virus 
CP   coat protein 
CPMV   Cowpea mosaic virus 
CPV  
C
cv.    cultivar 
Da    Dalton, g/mol 
D
DNA    desoxyribonucleic acid 
cDNA   complementary DNA 
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leotide triphosphate 
 inoculation 
 oid  
tetraacetic acid 
osorbent assay 
se virus 
phage colony stimulating factor 
 
virus 
us 
nse 
e 
 
 complexes 
 
nt 
dNTP    deoxynuc
dpi   days post
DT   diphtheria tox
DTT    dithiothreitol 
E. coli                          Escherichia coli 
EDTA    ethylenediamine
ELISA   enzyme-linked immun
ER    endoplasmic reticulum 
FcγR   Receptor for the Fc region of IgG 
F-Protein  Fusion Protein 
FMDV   Foot and mouth disea
G    guanin 
GFP   green fluorescent protein 
gm    gram  
GM-CSF  granulocyte-macro
G-Protein  RSV glycoprotein 
h    hour(s) 
HCV   Hepatitis C virus
HBS    Hepes buffered saline 
His    histidine 
HIV   Human immunodeficiency 
HLA   human leukocyte antigen 
HPIV   Human parainfluenza vir
HR   hypersensitive respo
HRP   horse radish peroxidas
HRV   Human rhino virus 
IFN   interferons 
Ig    immunoglobulin
IL   interleukine 
ISCOM  immunostimulating
JGMV   Johnsongrass mosaic potyvirus
KA    equilibrium association consta
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kDa    kilodalton 
kg    kilogram 
KI    inhibitory constant 
ocyanin 
ility complex 
 
ingspot virus 
MV genomic RNA1&2 
is 
r cells  
ining 0.05% (v/v) Tween20 
action 
    
te 
p  
KLH   keyhole limpet haem
Km    kanamycin 
l    liter(s)  
M    molarity (mol/L) 
mab    monoclonal antibody 
MAP   multiple antigen peptide 
MHC   major histocompatib
MHV   murine hepatitis virus  
min    minute(s) 
mRNA   messenger ribonucleic acid 
MV   Measles virus
MW    molecular weight 
NBT    nitro blue tetrazolium 
nm   nanometer 
OD    optical density 
OPD   o-Phenylenediamine 
ORSV   Odontoglossum r
P12   transgenic tobacco containing Al
PAGE    polyacrylamide gel electrophores
PBMC   peripheral blood mononuclea
PBS    phosphate buffered saline 
PBST    phosphate buffered saline conta
PCR    polymerase chain re
pI   iso-electric point 
PNPP    para-nitrophenylphospha
PPV   Plum pox virus 
PVX   Potato virus X 
rAb    recombinant antibody 
RdR   RNA dependent RNA polymerase
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rER   rough endoplasmic reticulum  
en presentation 
s 
 2 
c virus 
ic factor 
omethane 
merica 
RNA   ribonucleic acid 
rpm    rotations per minute 
RSV   respiratory syncytial virus 
RT    room temperature 
RV   rabies virus 
SDS    sodium dodecylsulfate 
T    thymin 
TAP   transporter associated with antig
Taq    Thermus aquaticus 
TBSV   tomato bushy stunt viru
TCR   T-cell receptor 
TH1, TH2  T-helper cells of subset 1 or 
TMV   Tobacco mosai
TMOV  trypsin modulating oostat
Tris    trishydroxymethylamin
USA    United States of A
UTR    untranslated region 
UV    ultraviolet 
V    Volt 
v/v    volume per volume 
w/v    weight per volume 
ZYMV  zucchini yellow mosaic virus 
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7.2 of no acids List  ami
etter Selected properties 
small 
small, polar 
negative charge 
utamic acid negative charge 
enylalanine bulky, hydrophobic 
small 
positive charge 
ucine branched-chain, hydrophobic 
ophobic 
hydrophobic 
polar 
kinked, polar 
ln polar 
positive charge 
small, polar 
small, polar 
l branched-chain, hydrophobic 
bulky, hydrophobic 
yr , hydrophobic 
RSV-F-primer sequence # 
I Primer  3’ SalI Primer rev.comp.  
1 ACCATGAGTTTTGCTTCTGGTCAA CCGGTCGACAAGATAGCCTTTGCT 
2 38 61 112 TAGTGCAGTTAGCAAA CCGGTCGACTAATTCTATAGTTAT 
3 54 77 160 CCGGTCGACTTTTACCTTAGCATC 
4 70 93 208 TAATGGAACAGATGCT CCGGTCGACCAATTCTGTTACAGC 
5 109 256 327 CCGGTCGACTCTTCTGGCTCGATT 
6 125 304 AATCGA CCGGTCGACGGTTTTTTTGGCATT 
7 118 141 352 423 CGGGGTACCATGAGTACACTCAACAATGCC CCGGTCGACCAAAAAACCAAGAAA 
8 134 157 400 471 CGGGGTACCATGAGTAAAAGAAGATTTCTT CCGGTCGACGACCTTAGATACAGC 
9 150 173 448 519 CGGGGTACCATGAGTAGTGGCGTTGCTGTA CCGGTCGACGGATAGTAGAGCACT 
10 166 189 496 567 CGGGGTACCATGAGTAAGATCAAAAGTGCT CCGGTCGACGGTTAAGACACTAAC 
11 182 205 544 615 CGGGGTACCATGAGTTCAAATGGAGTTAGT CCGGTCGACAGGTAACAATTGTTT 
12 198 221 592 663 CGGGGTACCATGAGTTATATAGATAAACAA CCGGTCGACTATCACAGTTTCTAT 
13 214 237 640 711 CGGGGTACCATGAGTATATCAAATATAGAA CCGGTCGACAAATTCCCTGGTAAT 
14 230 253 688 759 CGGGGTACCATGAGTAGACTACTAGAGATT CCGGTCGACTAACATGTAAGTGCT 
15 246 269 736 807 CGGGGTACCATGAGTCCTGTAAGCACTTAC CCGGTCGACATCATTTGTTATAGG 
16 262 285 784 855 CGGGGTACCATGAGTAATGATATGCCTATA CCGGTCGACACTTTGCTGTCTAAC 
17 278 301 832 903 CGGGGTACCATGAGTGTTCAAATAGTTAGA CCGGTCGACTACTACATATGCTAA 
18 294 317 880 951 CGGGGTACCATGAGTGAGGAAGTCTTAGCA CCGGTCGACGTGTAGTTTCCAACA 
19 310 333 928 999 CGGGGTACCATGAGTGATACACCCTGTTGG CCGGTCGACACAGATGTTGGACCC 
20 326 349 976 1047 CGGGGTACCATGAGTACAAAAGAAGGGTCC CCGGTCGACTACTGATCCTGCATT 
21 342 365 1024 1095 CGGGGTACCATGAGTTACTGTGACAATGCA CCGGTCGACTACTCGATTTGATTG 
 
 
Table 7-1: List of amino acids with selected properties 
1-letter code 3-l code Full name 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Gl
F Phe Ph
G Gly Glycine 
H His Histidine 
I Ile Isole
K Lys Lysine positive charge 
L Leu Leucine branched-chain, hydr
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q G Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Va Valine 
W Trp Tryptophan 
Y T Tyrosine bulky
7.3 List of oligonucleotides 
Table 7-2: RSV-F peptide primers 
RSV-Fusion 
Protein 
position Gene position 
first last first last 5' Kpn
22 45 64 135 CGGGGT
183 CGGGGTACCATGAG
231 CGGGGTACCATGAGTACCAGTGTTATAACT 
279 CGGGGTACCATGAG
86 CGGGGTACCATGAGTTATAAAAATGCTGTA 
102 375 CGGGGTACCATGAGTCCAACAAAC
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position 
RSV-F-primer sequence 
  3’ SalI Primer rev.comp.  
381 1143 CGGGGTACCATGAGTTGTAAAGTTCAATCA 
 3 1191 TGAGTACATTA CGACAGTCATAATTTTACA 
413 1168 1239 CATGAGTAAATAT AAA CCGGTCGACAATGGCTCCTAGAGA 
429 1216 1287 ATGAGTGTTATC CCGGTCGACACGATTTTTATTGGA 
445 1264 1335 GTTGTACA GGTCGACTTTATTTGATACATA 
461 1312 1383 GTGGGTGC GGTCGACCTTATTTACATAATA 
477 1360 1431 GTAACACA CGACGAAATTTATTATTGG 
493 1408 1479 CATGAGTAAAGGT ATA CCGGTCGACAGATATTGATGCATC 
509 1456 1527 ATGAGTGATGAA GGTCGACGGATTTACGAATAAA 
31 502 525 1504 1575 TGAGTAGCCTA TTGTGGTGGA 
541 1552 1623 CCATGAGTGCTGGT GGTCGACTAATGATAACAATAT 
557 1600 1671 CATGAGTATTATA GTGTGCTTCT 
4 550 573 1648 1719 GAGTTGTAAG CCGGTCGACGTTACTAAATGCAAT 
ble 7-3: RSV-Fb ptide primers 
is 102 125 304 375 TGAGTGAACTA  CCGGTCGACGCTTAATGTTACATTG 
bis 210 233 628 699 ATGAGTCAAAGC GGTCGACAATCTCTAGTAGTCTG 
bis 273 292 817 876 CCATGAGTTTAATG CCGGTCGACTATTATGGACATGATAG 
bis 282 299 844 897 TGAGTAGACAG CCGGTCGACATATGCTAAGACTTC 
bis 299 326 895 978 CCATGAGTTATGTA TGGTTGTAC 
is 403 426 1207 1278 GAGTAGCAGC CGACATTGGATGCTGTAC 
bis 414 426 1240 1278 ATGAGTGTGTCA CGACATTGGATGCTGTAC 
HR2 474 523 1420 1569 CGGGGTACCATGAGTATAATAAATTTCTATG  CCGGTCGACTGTGGTGGATTTACC 
ACCATGAGTTTTGATGCATCAATATC CCGGTCGACGGTGGATTTACCAGC 
Table 7-4: RSV-F-SSQ peptide primers 
1 CGGGGTACCATGAGTTCTTCTCAAGAGGAAGTC
TTAGCA 
CCGGTCGACGTGTAGTTTCCAACA 
8bis
SSQ 
8 CGGGGTACCATGAGTT
CAATTAC 
GACTGTGTTGGTTGTAC 
id
24b 403 42 20 C C 
bis 403 42 20 T GCTGTAC 
24b
DE 0 2 20
C GCTGTAC 
abl  R 25 L
5bi
LTL 1 2 24
G CAAAGAGT
5bi
ETE 1 2 24
G CATTCAGT
abl  H  m e
7A C GGAGGATC
12H T GATTCCAA
abl  S ci m
 
Nde B o
3’BamHI pBR-vector  CGAGGATCCGAGGTCCCGCGAAATCCT 
5’-96 gIII M13 CCCTCATAGTTAGCGTAACG  
RSV-Fusion 
Protein Gene position# 
first last first last 5' KpnI Primer
22 358 
23 374
1072 
97 1120 
CCGGTCGACGAGATTTATTTCACT 
CCAAGTGAA CCGGTCGGGGTACCA
24 390 CGGGGTAC GATTGT
25 406 CGGGGTACC ACATCTCTA 
26 422 CGGGGTACCATGA GCATCCAAT CC
27 438 CGGGGTACCATGA GATTATGTA CC
28 454 CGGGGTACCATGA TTATATTAT CCGGT
29 470 CGGGGTAC GAACCA
30 486 CGGGGTACC TTTGATGCA CC
CGGGGTACCA GCATTTATT CCGGTCGACGATAT
32 518 CGGGGTA AAATCCACC CC
33 534 CGGGGTAC GTAATATTG CCGGTCGACGACTG
3 CGGGGTACCAT GCCAGAAGC 
Ta is pe
6b CGGGGTACCA CCAAGG
12 CGGGGTACC TGCAGCATATC CC
16 CGGGGTA TCCAACAATG 
17 CGGGGTACCA CAAAGTTAC 
18 CGGGGTA GTACAATTAC CCGGTCGACTGTGT
24b CGGGGTACCAT TCCGTTATC CCGGT
25 CGGGGTACC TGCTATGGC CCGGT
118 488 522 1462 1566 CGGGGT
18 SSQ 294 317 880 95
1  299 326 895 97 CTTCTCAATATGTAGTACCGGTC
Table 7-5: RSV-F-DE pept e primers 
DE is  6 1 7 1278 TATC 
CGGGGTACCATGAGTGATGAAAGCAGCT CGT CCGGTCGACATTGGATGCTGTA
24 DE  6 1 7 1278 CGGGGTACCATGAGTAGCAGCTCCGTTA C CCGGTCGACTTCATCATTGGAT
DE is
 4 3 4 6 1 7 1278 TATC 
CGGGGTACCATGAGTGATGAAAGCAGCT CGT CCGGTCGACTTCATCATTGGAT
T e 7-6: SV-F- bis LT  and ETE peptide primers 
2 s 
 4 4 4 6 1 0 1278 TACTCTTTG 
CGGGGTACCATGAGTGTGTCATGCTATG CCT CCGGTCGACATTGGATGCTGTA
AAGGCCATAGC 
2 s 4 4 4 6 1 0 1278 
CGGGGTACCATGAGTGTGTCATGCTATG CGA CCGGTCGACATTGGATGCTGTA
AACTGAATGTAC TTCGCCATAGC 
T e 7-7: NK20 imic p ptide primers 
H 2     CCGGGTACCATGAGTGCTTGTACTAAGC ACT GCCACTTCAAAAGTCTTGTGGATCAAAAGTCTTG TGTCGACCGG 
H 2     CGGGGTACCATGAGTAGAATTAGAAATCTATGAAGATTCC 
TCT GAATTAGAAATCTTCTTATGAA
GAGAAGTCGACCGG 
T e 7-8: equen ng pri ers 
 Target 5'Primer 
TTACATATGAAAGTTTTATTAAAGATG 
3’Primer 
 5’ I p R-vect r 
 Curriculum vitae 
 
Name:  
Date o
P  o h
Nationality:  
r Munz 
t
r
Perman
E il:
o
 
 
 
 
E ati  e
 
1995 
1 -19
0
b a
i
 Albert-Ludwigs-University Freibur
u
s es
D c
n ri n or
er
n  
p
b
b i
urg; Department of Plant Physiol
F m
Jan.-Aug 2001 
T ac
Subject: Expression of the human cellular tumour a
 in Nicotiana tabacum and Escher
0  
2
se
ar
x
t
4
enter for Molecula
e
Publications and Presentations
Th lant urna
Im ired crose
biosynthe  gene
July 2003 
entation; annual meeting of the American
fa mos s a screening tool for im
y sync
 
 
f birth:  7th
lace f birt :  Ro
Georg Alexande
 October 1975 
tweil 
Ge man 
ent  
-ma   
Ge rg Munz 
georg_munz@yahoo.com 
duc on & Studi s 
995 96 
1996-1998 
1998-2001 
Biology studies;
Biotechnology s
“A itur” p ssed with distinction; Faust Gymnasium
Ziv ldienst; Naturfreundehaus Königstein, Sachsen 
2001 
2002-2
 
04 
t
is; RW
dies; Ecole Supérieure de Biotech
TH Aachen, Germany Ma ter-th
Ph -Proje t; Fraunhofer Center for Molecular Biote
Traini g Pe ods a d W k experiences 
 
Summ   
1999 
Joh  Innes Centre; Norwich, UK; 
De artment of Molecular Genetics, Prof. Mike Beva
Su ject: Gene-Mapping of four impaired sucrose in
Ara idops s thaliana using SSLP markers. 
Summer  University of Freibbj h2000 SuPcE
ect: C
1-pro
aract
otor.
erization of cis-elements via 5´-del
 
RW H A hen; Department of Molecular Biotechn
Virus core protein
Nov 20 1 to 
 Jan 200
Re arch Assistant, Fraunhofer Institute for Molecu
Ph
Subject:
maceu
 E
tical P
press
roduct Development group, Dr. Ste
ion of the Tobacco Mosaic Virus 3
 Hepatitis C, E1 and E2 protein inPro ein and of the
Jan 2002 to Research Assistant, Fraunhofer CSubject: CharactJul 200  erization of AlMV as peptide expre potential RSV-F epitopscr ening system to identify
 
 
 
2001 
e P  Jo l (2001) 26(4), 421-433  
pa su
tic
-induction mutants reveal the modu
 expression by abscisic acid signal
Poster pres
falCA: "Al aic virus a
Respirator ytial virus F- protein". 
 
  S
g 
n
ogy; Prof. Dr. Schäfer 
ntigen p53 and the Hepatitis C 
ichia coli (Diploma thesis). 
E. coli.
r Biotechnology  
 Society for Virology; Davis, 
m peptides from the 
taufen 
nologie de Strasbourg 
chnology, Newark, USA 
  
duction mutants in 
etion experiments in the 
ology, Prof. R. Fischer 
lar Biotechnology; 
fan Barth 
0
 
kDa movement and 54kDa 
 
s
es as vaccine candidates. 
sion, presentation, delivery 
l
li
ation of sugar-induced starch 
ng 
unogenic 
114                                                                                                                                           7 Appendix  
7 Appendix                                                                                                                                            115 
 
Zum Brunnen, der Krug, so lange; 
das Glück der Scherben,  
dem, der ihn trug. 
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